<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1295" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1295/" /><meta name="ncbi_pagename" content="COL1A1/2 Osteogenesis Imperfecta - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>COL1A1/2 Osteogenesis Imperfecta - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="COL1A1/2 Osteogenesis Imperfecta" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/12/12" /><meta name="citation_author" content="Robert D Steiner" /><meta name="citation_author" content="Donald Basel" /><meta name="citation_pmid" content="20301472" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1295/" /><meta name="citation_keywords" content="Brittle Bone Disease" /><meta name="citation_keywords" content="OI" /><meta name="citation_keywords" content="Brittle Bone Disease" /><meta name="citation_keywords" content="OI" /><meta name="citation_keywords" content="Collagen alpha-1(I) chain" /><meta name="citation_keywords" content="Collagen alpha-2(I) chain" /><meta name="citation_keywords" content="COL1A1" /><meta name="citation_keywords" content="COL1A2" /><meta name="citation_keywords" content="COL1A1/2 Osteogenesis Imperfecta" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="COL1A1/2 Osteogenesis Imperfecta" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Robert D Steiner" /><meta name="DC.Contributor" content="Donald Basel" /><meta name="DC.Date" content="2019/12/12" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1295/" /><meta name="description" content="COL1A1/2 osteogenesis imperfecta (COL1A1/2-OI) is characterized by fractures with minimal or absent trauma, variable dentinogenesis imperfecta (DI), and, in adult years, hearing loss. The clinical features of COL1A1/2-OI represent a continuum ranging from perinatal lethality to individuals with severe skeletal deformities, mobility impairments, and very short stature to nearly asymptomatic individuals with a mild predisposition to fractures, normal dentition, normal stature, and normal life span. Fractures can occur in any bone but are most common in the extremities. DI is characterized by gray or brown teeth that may appear translucent, wear down, and break easily. COL1A1/2-OI has been classified into four types based on clinical presentation and radiographic findings. This classification system can be helpful in providing information about prognosis and management for a given individual. The four more common OI types are now referred to as follows:" /><meta name="og:title" content="COL1A1/2 Osteogenesis Imperfecta" /><meta name="og:type" content="book" /><meta name="og:description" content="COL1A1/2 osteogenesis imperfecta (COL1A1/2-OI) is characterized by fractures with minimal or absent trauma, variable dentinogenesis imperfecta (DI), and, in adult years, hearing loss. The clinical features of COL1A1/2-OI represent a continuum ranging from perinatal lethality to individuals with severe skeletal deformities, mobility impairments, and very short stature to nearly asymptomatic individuals with a mild predisposition to fractures, normal dentition, normal stature, and normal life span. Fractures can occur in any bone but are most common in the extremities. DI is characterized by gray or brown teeth that may appear translucent, wear down, and break easily. COL1A1/2-OI has been classified into four types based on clinical presentation and radiographic findings. This classification system can be helpful in providing information about prognosis and management for a given individual. The four more common OI types are now referred to as follows:" /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1295/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/oi/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1295/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE897BB5E040F0C100000000039F01AA.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1295_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1295_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/clpb-def/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/col4a1-dis/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1295_"><span class="title" itemprop="name"><i>COL1A1/2</i> Osteogenesis Imperfecta</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Brittle Bone Disease, OI</div><p class="contrib-group"><span itemprop="author">Robert D Steiner</span>, MD and <span itemprop="author">Donald Basel</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1295_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1295_ai__"><div class="contrib half_rhythm"><span itemprop="author">Robert D Steiner</span>, MD<div class="affiliation small">Marshfield Clinic Health System<br />Marshfield, Wisconsin</div><div class="affiliation small">University of Wisconsin<br />Madison, Wisconsin<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.liamg@111renietsdr" class="oemail">moc.liamg@111renietsdr</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Donald Basel</span>, MD<div class="affiliation small">Medical College of Wisconsin<br />Milwaukee, Wisconsin<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.wcm@lesabd" class="oemail">ude.wcm@lesabd</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">January 28, 2005</span>; Last Revision: <span itemprop="dateModified">December 12, 2019</span>.</p><p><em>Estimated reading time: 42 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="oi.Summary" itemprop="description"><h2 id="_oi_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>COL1A1/2</i> osteogenesis imperfecta (<i>COL1A1/2</i>-OI) is characterized by fractures with minimal or absent trauma, variable dentinogenesis imperfecta (DI), and, in adult years, hearing loss. The clinical features of <i>COL1A1/2</i>-OI represent a continuum ranging from perinatal lethality to individuals with severe skeletal deformities, mobility impairments, and very short stature to nearly asymptomatic individuals with a mild predisposition to fractures, normal dentition, normal stature, and normal life span. Fractures can occur in any bone but are most common in the extremities. DI is characterized by gray or brown teeth that may appear translucent, wear down, and break easily. <i>COL1A1/2</i>-OI has been classified into four types based on clinical presentation and radiographic findings. This classification system can be helpful in providing information about prognosis and management for a given individual. The four more common OI types are now referred to as follows:</p><ul><li class="half_rhythm"><div>Classic non-deforming OI with blue sclerae (previously OI type I)</div></li><li class="half_rhythm"><div>Perinatally lethal OI (previously OI type II)</div></li><li class="half_rhythm"><div>Progressively deforming OI (previously OI type III)</div></li><li class="half_rhythm"><div>Common variable OI with normal sclerae (previously OI type IV)</div></li></ul></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of <i>COL1A1/2</i>-OI is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic or <a class="def" href="/books/n/gene/glossary/def-item/likely-pathogenic/">likely pathogenic variant</a> in <i>COL1A1</i> or <i>COL1A2</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Ideally, management is by a multidisciplinary team including specialists in medical management of OI, clinical genetics, orthopedics, rehabilitation medicine, pediatric dentistry, otology/otolaryngology, and mental health. Parents / other caregivers must practice safe handling techniques. Mainstays of treatment include: bracing of limbs depending on OI severity; orthotics to stabilize lax joints; physical activity; physical and occupational therapy to maximize bone stability, improve mobility, prevent contractures, prevent head and spine deformity, and improve muscle strengthening; mobility devices as needed; and pain management. Fractures are treated with: as short a period of immobility as is practical; small and lightweight casts; physical therapy as soon as casts are removed; and intramedullary rodding when indicated to provide anatomic positioning of limbs. Progressive scoliosis in severe OI may not respond well to conservative or surgical management. Bisphosphonates continue to be used most extensively in severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children with OI. Surgical treatment for basilar impression should be done in a center experienced in the necessary procedures. Dental care strives to maintain both primary and permanent dentition, a functional bite or occlusion, optimal gingival health, and overall appearance. Conductive hearing loss may be improved with middle ear surgery; later-onset sensorineural hearing loss is treated in the same manner as when caused by other conditions. Mental health support through psychiatry/psychology and appropriate social worker intervention can improve quality of life.</p><p><i>Prevention of secondary complications:</i> During general anesthesia, proper positioning on the operating room table and use of cushioning such as egg crate foam can help avoid fractures.</p><p><i>Surveillance:</i> Orthopedic evaluation with ancillary therapy services (physical and rehabilitation medicine) as indicated every three months until age one year, every six months from ages one to three years, and then annually or with any new fractures. Physical therapy evaluation in infancy for those with motor delays and as needed to improve mobility and function. CT and/or MRI examination with views across the base of the skull to evaluate for basilar impression if concerning signs or symptoms are present. Cervical spine flexion and extension radiographs in children able to cooperate with the examination or before participating in sporting activities in more mildly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. Twice-yearly dental visits beginning in early childhood or even infancy for those with (or at risk for) DI. Hearing evaluation at three- to five-year intervals from age five years until hearing loss is identified, then as indicated based on the nature and degree of hearing loss and associated interventions.</p><p><i>Agents/circumstances to be avoided:</i> Contact sports should be avoided.</p></div><div><h4 class="inline">Genetic counseling.</h4><p><i>COL1A1/2</i>-OI is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. The proportion of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals who represent <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence of the disorder in a family) varies by the severity of disease. Approximately 60% of probands with mild OI represent simplex cases. Virtually 100% of probands with progressively deforming or perinatally lethal OI represent simplex cases and have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> or a pathogenic variant inherited from a parent with somatic and/or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>. Parental somatic and/or germline mosaicism is present in up to 16% of families. Each child of an individual with a dominantly inherited form of <i>COL1A1/2</i>-OI has a 50% chance of inheriting the causative variant and of developing some manifestations of OI. Prenatal testing in at-risk pregnancies can be performed by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if the <i>COL1A1</i> or <i>COL1A2</i> causative variant has been identified in an affected relative. Ultrasound examination performed in a center with experience in diagnosing OI can be valuable in the <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> of the lethal form and most severe forms prior to 20 weeks' gestation; milder forms may be detected later in pregnancy if fractures or deformities occur.</p></div></div><div id="oi.Diagnosis"><h2 id="_oi_Diagnosis_">Diagnosis</h2><p>An algorithm for the diagnosis of osteogenesis imperfecta (OI) has been published [<a class="bk_pop" href="#oi.REF.basel.2009.375">Basel &#x00026; Steiner 2009</a>]. See <a class="figpopup" href="/books/NBK1295/figure/oi.F1/?report=objectonly" target="object" rid-figpopup="figoiF1" rid-ob="figoboiF1">Figure 1</a>.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figoiF1" co-legend-rid="figlgndoiF1"><a href="/books/NBK1295/figure/oi.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figoiF1" rid-ob="figoboiF1"><img class="small-thumb" src="/books/NBK1295/bin/oi-Image001.gif" src-large="/books/NBK1295/bin/oi-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndoiF1"><h4 id="oi.F1"><a href="/books/NBK1295/figure/oi.F1/?report=objectonly" target="object" rid-ob="figoboiF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Recommended testing algorithm for evaluation of osteogenesis imperfecta Adapted from Basel &#x00026; Steiner [2009]</p></div></div><div id="oi.Suggestive_Findings"><h3>Suggestive Findings</h3><p><i>COL1A1/2</i> osteogenesis imperfecta (OI) <b>should be suspected</b> in individuals with the following clinical, radiographic, and laboratory features.</p><p><b>Clinical features</b> (<a class="figpopup" href="/books/NBK1295/table/oi.T.clinical_features_of_col1a12_osteog/?report=objectonly" target="object" rid-figpopup="figoiTclinicalfeaturesofcol1a12osteog" rid-ob="figoboiTclinicalfeaturesofcol1a12osteog">Table 1</a>)</p><ul><li class="half_rhythm"><div><b>Fractures</b> with minimal or no trauma in the absence of other factors, such as non-accidental trauma (NAT) or other known disorders of bone</div></li><li class="half_rhythm"><div><b>Short stature</b> or stature shorter than predicted based on stature of unaffected family members, often with <b>bone deformity</b></div></li><li class="half_rhythm"><div><b>Blue/gray scleral hue</b></div></li><li class="half_rhythm"><div><b>Dentinogenesis imperfecta</b> (DI)</div></li><li class="half_rhythm"><div><b>Progressive, postpubertal hearing loss</b></div></li><li class="half_rhythm"><div><b>Ligamentous laxity</b> and other signs of connective tissue abnormality</div></li><li class="half_rhythm"><div><b>Family history</b> of OI, usually consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance</div></li></ul><div id="oi.T.clinical_features_of_col1a12_osteog" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Clinical Features of <i>COL1A1/2</i> Osteogenesis Imperfecta by Type</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1295/table/oi.T.clinical_features_of_col1a12_osteog/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__oi.T.clinical_features_of_col1a12_osteog_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Type</th><th id="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severity</th><th id="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Fractures</th><th id="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bone Deformity</th><th id="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Stature</th><th id="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_7" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DI</th><th id="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_8" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sclerae</th><th id="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_9" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hearing Loss</th></tr></thead><tbody><tr><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Classic non-deforming OI w/blue sclerae</b></td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Few to 100</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Uncommon</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal or slightly short for family</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rare</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Blue</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Present in ~50%</td></tr><tr><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Perinatally lethal OI</b></td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Perinatal lethal</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Multiple fracture of ribs, minimal calvarial mineralization, platyspondyly, marked compression of long bones</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severely short</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dark blue</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02014;</td></tr><tr><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Progressively deforming OI</b></td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Thin ribs, platyspondyly, thin gracile bones w/many fractures, "popcorn" epiphyses common</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Moderate to severe</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Very short</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Blue</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequent</td></tr><tr><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Common variable OI w/normal sclerae</b></td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Moderate to mild</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Multiple</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild to moderate</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variably short</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+/&#x02013;</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal to gray</td><td headers="hd_h_oi.T.clinical_features_of_col1a12_osteog_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Some</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; DI = dentinogenesis imperfecta; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a></p></div></dd></dl></div></div></div><p><b>Radiographic features of OI</b> change with age. The major findings include the following (<a class="figpopup" href="/books/NBK1295/table/oi.T.radiographic_findings_of_col1a12_os/?report=objectonly" target="object" rid-figpopup="figoiTradiographicfindingsofcol1a12os" rid-ob="figoboiTradiographicfindingsofcol1a12os">Table 2</a>):</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Fractures</b> of varying ages and stages of healing, often of the long bones but may also rarely involve ribs and skull. Metaphyseal fractures can be seen in a very small number of children with OI. Rib fractures are much more common in NAT than in OI.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>"Codfish" vertebrae,</b> which are the consequence of spinal compression fractures, seen more commonly in adults</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Wormian bones,</b> defined as "sutural bones which are 6 mm by 4 mm (in diameter) or larger, in excess of ten in number, with a tendency to arrangement in a mosaic pattern" [<a class="bk_pop" href="#oi.REF.cremin.1982.35">Cremin et al 1982</a>]. Wormian bones are suggestive of but not pathognomonic for OI.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Protrusio acetabuli,</b> in which the socket of the hip joint is too deep and the acetabulum bulges into the cavity of the pelvis causing intrapelvic protrusion of the acetabulum</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Low bone mass</b> or osteoporosis detected by dual energy x-ray absorptiometry (DEXA). Bone density can be normal, especially in individuals with OI type I, as DEXA measures mineral content rather than collagen [<a class="bk_pop" href="#oi.REF.deodhar.1994.463">Deodhar &#x00026; Woolf 1994</a>, <a class="bk_pop" href="#oi.REF.paterson.1994.104">Paterson &#x00026; Mole 1994</a>, <a class="bk_pop" href="#oi.REF.cepollaro.1999.129">Cepollaro et al 1999</a>, <a class="bk_pop" href="#oi.REF.lund.1999.1083">Lund et al 1999</a>].</div><div class="half_rhythm">Note: (1) A major determinant of bone density may be the individual's ability to ambulate. (2) Bone density standards for children under age two years have been determined after sampling very small populations (often &#x0003c;10 persons); thus, reliability is an issue. (3) Bone density standards for children are based on height; corrections for short stature of severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals need to be made. (4) Bone density is not typically measured in children before age four years because of their inability to lie still, though this may be accomplished with patience in sleeping infants. (5) The purpose of measuring bone density in individuals known to have OI is to allow for monitoring of the individual's bone density over time, and not for comparison with unaffected individuals.</div></li></ul><div id="oi.T.radiographic_findings_of_col1a12_os" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Radiographic Findings of <i>COL1A1/2</i> Osteogenesis Imperfecta by Type</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1295/table/oi.T.radiographic_findings_of_col1a12_os/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__oi.T.radiographic_findings_of_col1a12_os_lrgtbl__"><table><thead><tr><th id="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Type</th><th id="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severity</th><th id="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Skull</th><th id="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Back</th><th id="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Extremities</th><th id="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Other</th></tr></thead><tbody><tr><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Classic non-deforming OI w/blue sclerae</b></td><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild</td><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Wormian bones</td><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Codfish vertebrae (adults)</td><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Thin cortices</td><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Osteopenia</td></tr><tr><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Perinatally lethal OI</b></td><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Perinatal lethal</td><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Undermineralization; plaques of calcification</td><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Platyspondyly</td><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severely deformed; broad, crumpled, bent femurs</td><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Small beaded ribs (pathognomonic)</td></tr><tr><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Progressively deforming OI</b></td><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe</td><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Wormian bones</td><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Codfish vertebrae; kyphoscoliosis</td><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Flared metaphyses ("popcorn"-like appearance in childhood), bowing, thin cortices</td><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Thin ribs, severe osteoporosis</td></tr><tr><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Common variable OI w/normal sclerae</b></td><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Intermediate</td><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x000b1; wormian bones</td><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Codfish vertebrae</td><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Thin cortices</td><td headers="hd_h_oi.T.radiographic_findings_of_col1a12_os_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Protrusio acetabuli in a subset</td></tr></tbody></table></div></div><p><b>Laboratory features</b></p><ul><li class="half_rhythm"><div><b>Serum concentrations</b> of vitamin D, calcium, phosphorous, and alkaline phosphatase are typically normal; however, alkaline phosphatase may be elevated acutely in response to fracture and rare instances of abnormally low alkaline phosphatase levels have been noted anecdotally in severe OI.</div></li><li class="half_rhythm"><div><b>Analysis of type 1 collagen</b> synthesized in vitro by culturing dermal fibroblasts obtained from a small skin biopsy reflects the structure and quantity of the collagen. The <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of biochemical testing is approximately 90% in individuals with clinically confirmed OI [<a class="bk_pop" href="#oi.REF.wenstrup.1990.975">Wenstrup et al 1990</a>; PH Byers, personal communication]. Biochemical analysis is essentially no longer used clinically with the advances in molecular diagnostics.</div></li></ul><div id="oi.Establishing_the_Diagnosis"><h4>Establishing the Diagnosis</h4><p>The diagnosis of <i>COL1A1/2</i>-OI <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic or <a class="def" href="/books/n/gene/glossary/def-item/likely-pathogenic/">likely pathogenic variant</a> in <i>COL1A1</i> or <i>COL1A2</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1295/table/oi.T.molecular_genetic_testing_used_in_c/?report=objectonly" target="object" rid-figpopup="figoiTmoleculargenetictestingusedinc" rid-ob="figoboiTmoleculargenetictestingusedinc">Table 3</a>). An approach to the molecular diagnosis of OI has been published (see <a class="figpopup" href="/books/NBK1295/figure/oi.F2/?report=objectonly" target="object" rid-figpopup="figoiF2" rid-ob="figoboiF2">Figure 2</a>) [<a class="bk_pop" href="#oi.REF.van_dijk.2012.11">van Dijk et al 2012</a>], but such approaches are in flux as technology is changing rapidly.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figoiF2" co-legend-rid="figlgndoiF2"><a href="/books/NBK1295/figure/oi.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="figoiF2" rid-ob="figoboiF2"><img class="small-thumb" src="/books/NBK1295/bin/oi-Image002.gif" src-large="/books/NBK1295/bin/oi-Image002.jpg" alt="Figure 2. " /></a><div class="icnblk_cntnt" id="figlgndoiF2"><h4 id="oi.F2"><a href="/books/NBK1295/figure/oi.F2/?report=objectonly" target="object" rid-ob="figoboiF2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">Preferred diagnostic flow in OI The approach to diagnosis is designed to maximize the likelihood that causative variants will be identified in all affected individuals or assign those without causative variants to research pools. This flow assumes that <a href="/books/NBK1295/figure/oi.F2/?report=objectonly" target="object" rid-ob="figoboiF2">(more...)</a></p></div></div><p>Molecular genetic testing approaches can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (concurrent gene testing, <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) and <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>) depending on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p></div><div id="oi.Option_1"><h4>Option 1</h4><p>When the phenotypic and laboratory findings suggest the diagnosis of <i>COL1A1/2</i>-OI, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches can include <b>concurrent <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Concurrent <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>COL1A1</i> and <i>COL1A2</i> detects small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-gene deletions/duplications are not detected. Perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> first. If no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found, perform gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> to detect intragenic deletions or duplications.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>COL1A1</i>, <i>COL1A2</i>, and other genes of interest (see <a href="#oi.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests. For this disorder, a multigene panel that also includes deletion/duplication analysis is recommended (see <a class="figpopup" href="/books/NBK1295/table/oi.T.molecular_genetic_testing_used_in_c/?report=objectonly" target="object" rid-figpopup="figoiTmoleculargenetictestingusedinc" rid-ob="figoboiTmoleculargenetictestingusedinc">Table 3</a>).</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul></div><div id="oi.Option_2"><h4>Option 2</h4><p>When the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is indistinguishable from many other inherited disorders characterized by bone fragility and/or skeletal dysplasia, <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) is the best option. <b>Exome sequencing</b> is most commonly used; <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b> is also possible and becoming more widely available.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="oi.T.molecular_genetic_testing_used_in_c" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>COL1A1/2</i> Osteogenesis Imperfecta</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1295/table/oi.T.molecular_genetic_testing_used_in_c/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__oi.T.molecular_genetic_testing_used_in_c_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_oi.T.molecular_genetic_testing_used_in_c_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_oi.T.molecular_genetic_testing_used_in_c_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1,&#x000a0;2</sup></th><th id="hd_h_oi.T.molecular_genetic_testing_used_in_c_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_oi.T.molecular_genetic_testing_used_in_c_1_1_1_2" style="text-align:left;vertical-align:middle;">Proportion of OI<br />Attributed to Pathogenic<br />Variants in Gene</th><th id="hd_h_oi.T.molecular_genetic_testing_used_in_c_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>3</sup> Detectable by Method</th></tr><tr><th headers="hd_h_oi.T.molecular_genetic_testing_used_in_c_1_1_1_3" id="hd_h_oi.T.molecular_genetic_testing_used_in_c_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></th><th headers="hd_h_oi.T.molecular_genetic_testing_used_in_c_1_1_1_3" id="hd_h_oi.T.molecular_genetic_testing_used_in_c_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></th></tr></thead><tbody><tr><td headers="hd_h_oi.T.molecular_genetic_testing_used_in_c_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>COL1A1</i></td><td headers="hd_h_oi.T.molecular_genetic_testing_used_in_c_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~5%-70%&#x000a0;<sup>6</sup></td><td headers="hd_h_oi.T.molecular_genetic_testing_used_in_c_1_1_1_3 hd_h_oi.T.molecular_genetic_testing_used_in_c_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;95%&#x000a0;<sup>7</sup></td><td headers="hd_h_oi.T.molecular_genetic_testing_used_in_c_1_1_1_3 hd_h_oi.T.molecular_genetic_testing_used_in_c_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1%-2%&#x000a0;<sup>8</sup></td></tr><tr><td headers="hd_h_oi.T.molecular_genetic_testing_used_in_c_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>COL1A2</i></td><td headers="hd_h_oi.T.molecular_genetic_testing_used_in_c_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~5%-30&#x000a0;<sup>6</sup></td><td headers="hd_h_oi.T.molecular_genetic_testing_used_in_c_1_1_1_3 hd_h_oi.T.molecular_genetic_testing_used_in_c_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;95%&#x000a0;<sup>7</sup></td><td headers="hd_h_oi.T.molecular_genetic_testing_used_in_c_1_1_1_3 hd_h_oi.T.molecular_genetic_testing_used_in_c_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1%-2%&#x000a0;<sup>8</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="oi.TF.3.1"><p class="no_margin">Genes are listed in alphabetic order.</p></div></dd><dt>2. </dt><dd><div id="oi.TF.3.2"><p class="no_margin">See <a href="/books/NBK1295/#oi.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>3. </dt><dd><div id="oi.TF.3.3"><p class="no_margin">See <a href="#oi.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>4. </dt><dd><div id="oi.TF.3.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="oi.TF.3.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="oi.TF.3.6"><p class="no_margin">PH Byers, personal communication</p></div></dd><dt>7. </dt><dd><div id="oi.TF.3.7"><p class="no_margin">Sequence analysis of <i>COL1A1</i> and <i>COL1A2</i> <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> to detect pathogenic variants in the coding sequence and <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>COL1A1</i> and <i>COL1A2</i> <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA to detect pathogenic variants that alter either sequence or stability of <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> identify close to 100% of pathogenic variants in these two genes.</p></div></dd><dt>8. </dt><dd><div id="oi.TF.3.8"><p class="no_margin"><a class="bk_pop" href="#oi.REF.van_dijk.2010.736">van Dijk et al [2010]</a> and data derived from Human Gene Mutation Database [<a class="bk_pop" href="#oi.REF.stenson.2017.665">Stenson et al 2017</a>]</p></div></dd></dl></div></div></div></div></div></div><div id="oi.Clinical_Characteristics"><h2 id="_oi_Clinical_Characteristics_">Clinical Characteristics</h2><div id="oi.Clinical_Description"><h3>Clinical Description</h3><p>The severity of <i>COL1A1/2</i> osteogenesis imperfecta (<i>COL1A1/2</i>-OI) ranges from perinatal lethality to individuals with severe skeletal deformities, mobility impairments, and very short stature to nearly asymptomatic individuals with a mild predisposition to fractures, normal stature, and normal life span.</p><p><i>COL1A1/2</i>-OI is classified into four more common types based on clinical presentation, radiographic features, family history, and natural history [<a class="bk_pop" href="#oi.REF.sillence.1979.101">Sillence et al 1979</a>]. An update of the Sillence classification has been proposed and has gained some acceptance [<a class="bk_pop" href="#oi.REF.emery.2012">Emery &#x00026; Rimoin 2012</a>]. Although this classification of <i>COL1A1/2</i>-OI into types is helpful in providing information about prognosis and management of a given individual, the features of different types of <i>COL1A1/2</i>-OI overlap and it is not always easy to categorize the extent of the clinical disorder. It is helpful to remember that the severity of clinical and radiographic features lies on a continuum and that the "types" are defined using characteristics that appear to form clinical "nodes." Interfamilial variability is apparent among individuals with the same OI type and <a class="def" href="/books/n/gene/glossary/def-item/intrafamilial-variability/">intrafamilial variability</a> is apparent among individuals with the same causative variant. Nonetheless, it is reasonable to continue to think of <i>COL1A1/2</i>-OI in terms of these types in order to provide information about the expected natural history of the disorder.</p><p><b>Classic non-deforming OI with blue sclerae (previously OI type I)</b> is characterized by blue sclerae and normal stature. A small proportion of infants with OI type I have femoral bowing at birth. The first fractures may occur at birth or with diapering. More often, the first fractures occur when the infant begins to walk and, more importantly, to fall. Fractures generally occur at a rate of a few to several per year and then decrease in frequency after puberty. Fracture frequency often increases again in adulthood, especially in postmenopausal women and men beyond the fifth decade [<a class="bk_pop" href="#oi.REF.paterson.1984.1694">Paterson et al 1984</a>]. Affected individuals may have anywhere from a few fractures to more than 100, but the fractures usually heal normally with no resulting deformity.</p><p>Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have normal or near normal stature but are often shorter than other members of their families and shorter than predicted based on parental heights.</p><p>Joint hypermobility predisposes to a number of minor comorbidities. The primary clinical concern is early-onset degenerative joint disease due to malalignment of articular surfaces.</p><p>In their classification of OI, <a class="bk_pop" href="#oi.REF.sillence.1979.101">Sillence et al [1979]</a> designated a subset of classic non-deforming OI with dentinogenesis imperfecta (DI) (OI type IB). In individuals with DI, morbidity results not from dental decay but rather from premature wearing down of the teeth. DI can be a significant cosmetic concern. Dental eruption in classic non-deforming OI can sometimes occur early.</p><p>Progressive hearing loss occurs in about 50% of adults with classic non-deforming OI, beginning as a conductive hearing loss but often with an additional sensorineural hearing loss component in time.</p><p><b>Perinatally lethal OI (previously OI type II).</b> Abnormalities characteristic of perinatally lethal OI are evident at birth. Weight and length are small for gestational age. The sclerae are dark blue and connective tissue is extremely fragile. The skull is large for the body size and soft to palpation. Callus formation on the ribs may be palpable. Extremities are short and bowed. Hips are usually flexed and abducted in a "frog-leg" position. Although some fetuses with perinatally lethal OI die in utero or are spontaneously aborted, more typically infants die in the immediate perinatal period. More than 60% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> infants die on the first day; 80% die within the first week; survival beyond one year is exceedingly rare and usually involves intensive support such as continuous assisted ventilation [<a class="bk_pop" href="#oi.REF.byers.1988.237">Byers et al 1988</a>]. Death usually results from pulmonary insufficiency related to the small thorax, rib fractures, or flail chest because of unstable ribs. Those who survive the first few days of life may not be able to ingest sufficient calories because of respiratory distress.</p><p>Histologic evaluation of bone from infants with perinatally lethal OI shows marked reduction in collagen in secondary trabeculae and cortical bone [<a class="bk_pop" href="#oi.REF.horton.1980.19">Horton et al 1980</a>]. Cortical bone is hypercellular with large osteocytes. Trabeculae contain woven bone with large immature osteoblasts [<a class="bk_pop" href="#oi.REF.cole.1992.112">Cole et al 1992</a>, <a class="bk_pop" href="#oi.REF.cole.1995.284">Cole &#x00026; Dalgleish 1995</a>].</p><p><b>Progressively deforming OI (previously OI type III).</b> The diagnosis of progressively deforming OI is readily apparent at birth. Fractures in the newborn period, simply with handling of the infant, are common. In some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> infants, the number and severity of rib fractures lead to death from pulmonary failure in the first few weeks or months of life.</p><p>Infants who survive this period generally fare well, although most do not walk without assistance and usually use a wheelchair or other assistance for mobility because of severe bone fragility and marked bone deformity. Affected individuals have as many as 200 fractures and progressive deformity even in the absence of obvious fracture. Progressively deforming OI is often difficult to manage orthopedically, even with intramedullary rod placement.</p><p>Growth is extremely delayed and adults with progressively deforming OI are among the shortest individuals known, with some having adult stature of less than one meter.</p><p>Intellect is normal unless there have been intracerebral hemorrhages (extremely rare). <a class="bk_pop" href="#oi.REF.faqeih.2009.461">Faqeih et al [2009]</a> published a report identifying increased risk for intracranial hemorrhage (ICH) in a "small number" of individuals who were identified to have pathogenic variants affecting <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 49 of <i>COL1A2</i>, which codes for the most carboxy-terminal part of the triple-helical <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of the collagen alpha-2(I) chain. They concluded that this <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> appeared to increase the risk for abnormal limb development and intracranial bleeding. <a class="bk_pop" href="#oi.REF.budsamongkol.2019.138">Budsamongkol et al [2019]</a> reported a young boy with marked joint hypermobility, significant DI, brachydactyly, and a <i>COL1A2</i> pathogenic variant found to be associated with ICH by <a class="bk_pop" href="#oi.REF.faqeih.2009.461">Faqeih et al [2009]</a>. The boy had not experienced an ICH, but as some of the original <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals only presented with ICH in their teenage years, this does not eliminate the risk in this young individual.</p><p>Even within progressively deforming OI, considerable heterogeneity is observed at the clinical level. Some individuals have normal-appearing teeth and facies while others have DI, a large head, and enlarged ventricles that reflect the soft calvarium. Relative macrocephaly and barrel chest deformity are observed. Usually sclerae are blue in infancy but lighten with age. Hearing loss generally begins in the teenage years. As molecular testing of this subgroup further differentiates those with <i>COL1A1/2</i>-OI from the <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> forms, the clinical profile of this heterogeneous group will become more refined.</p><p>Basilar impression, an abnormality of the craniovertebral junction caused by descent of the skull on the cervical spine, is common. Basilar impression is characterized by invagination of the margins of the foramen magnum upward into the skull, resulting in protrusion of the odontoid process into the foramen magnum. Basilar impression may progress to brain stem compression, obstructive hydrocephalus, or syringomyelia because of direct mechanical blockage of normal CSF flow [<a class="bk_pop" href="#oi.REF.charnas.1993.2603">Charnas &#x00026; Marini 1993</a>, <a class="bk_pop" href="#oi.REF.sillence.1994.427">Sillence 1994</a>, <a class="bk_pop" href="#oi.REF.hayes.1999.357">Hayes et al 1999</a>]. Symptoms of basilar impression become apparent with neck flexion. Findings include posterior skull pain, C2 sensory deficit, tingling in the fourth and fifth digits, and numbness in the medial forearm. When swimming, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals may perceive that water temperature differs below and above the umbilicus. Lhermitte's sign (tingling on neck flexion) can be demonstrated at any stage. Basilar impression can cause headache with coughing, trigeminal neuralgia, loss of function of the extremities, or paresthesias. At its most severe involvement, sleep apnea and death can occur.</p><p><b>Common variable OI with normal sclerae (previously OI type IV)</b> is characterized by mild short stature, DI, adult-onset hearing loss, and normal-to-gray sclerae. This is the most variable form of OI, ranging in severity from moderately severe to so mild that it may be difficult to make the diagnosis.</p><p>Stature is variable and may vary markedly within the family. DI is common but may be mild. Sclerae are typically light blue or gray at birth but quickly lighten to near normal. Hearing loss occurs in some and basilar impression can occur.</p><div id="oi.Other_Considerations"><h4>Other Considerations</h4><p><b>Facial features.</b> Infants and children with OI are often described as having a triangular face. The skull is relatively large compared to body size.</p><p><b>Other skeletal problems.</b> Individuals with OI may also have scoliosis, early-onset arthritis, non-inflammatory arthralgia, and myofascial pain.</p><p><b>Skin.</b> Easy bruising is a frequent observation in individuals with OI. This is believed to be caused by microvascular fragility and poor microstructural support of the connective tissues.</p><p><b>Hearing loss.</b> Mixed conductive and sensorineural hearing loss afflicts the majority of adults with OI. Childhood-onset hearing loss affects approximately 7% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children between ages five and nine years; progressive postpubertal hearing loss is more typical. The initial conductive hearing loss results from fractures of the bones of the middle ear with contracture and scarring of the incus. With age, sensorineural hearing loss compounds the preexisting conductive element. Fixation of the stapes is not unlike otosclerosis and surgical techniques such as stapedotomy used to treat otosclerosis have shown similar success in treating hearing loss in OI [<a class="bk_pop" href="#oi.REF.van_der_rijt.2003.717">van der Rijt &#x00026; Cremers 2003</a>, <a class="bk_pop" href="#oi.REF.kuurila.2004.187">Kuurila et al 2004</a>, <a class="bk_pop" href="#oi.REF.doi.2007.226">Doi et al 2007</a>]. Bisphosphonate therapy has not been shown to influence hearing loss.</p><p><b>Gastrointestinal.</b> Although complaints of constipation are common in adults with OI who are mobile in wheelchairs, it is not clear if this is a complication of OI itself or of the mode of transport. Bowel obstruction can occur as a result of protrusio acetabuli [<a class="bk_pop" href="#oi.REF.lee.1995.1352">Lee et al 1995</a>] but appears to be uncommon.</p><p><b>Cardiovascular.</b> Emerging data support an increased risk for cardiac and vascular disease in OI. <a class="bk_pop" href="#oi.REF.ashournia.2015.149">Ashournia et al [2015]</a> performed a systematic review of the literature in 2015 documenting a broad array of cardiovascular phenotypes with higher prevalence in individuals with a clinical diagnosis of OI including arterial and aortic dissection. <a class="bk_pop" href="#oi.REF.balasubramanian.2019.191">Balasubramanian et al [2019]</a> reported three additional individuals with <i>COL1A1/2</i>-OI and aortic aneurysms. There is still no consensus on cardiovascular surveillance, although some centers have initiated screening echocardiograms every three to five years to monitor for this risk.</p><p><b>Development.</b> Cognition is expected to be normal but gross motor development may be hindered by joint hypermobility and progressive deformity due to recurrent fractures.</p><p><b>Functional limitations.</b> Individuals with OI may experience other functional limitations, although these will be highly dependent on the specific physical manifestations of OI.</p><p><b>Life expectancy.</b> The severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> neonates with perinatally lethal OI typically do not survive, with a significant proportion of infants dying within the first 48 hours. Aggressive life support can prolong survival but ultimately the most severe forms remain perinatally lethal. Life expectancy for classic non-deforming OI and common variable OI is normal. Progressively deforming OI is highly variable and life expectancy may be shortened by the presence of severe kyphoscoliosis with attendant restrictive pulmonary disease resulting in cardiac insufficiency.</p></div></div><div id="oi.Phenotype_Correlations_by_Gene"><h3>Phenotype Correlations by Gene</h3><p>Most commonly OI results from pathogenic <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> variants in either of the genes encoding the alpha helical chains of type 1 collagen that form the collagen triple helical molecule. Quantitative impacts on type 1 collagen tend to result in a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> when compared to qualitative changes due to a <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> effect. Loss-of-function variants generally are associated with classic non-deforming OI with blue sclerae (previously OI type I).</p><p>In general, a clear <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlation does not exist. General rules for <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> in <i>COL1A1/2</i>-OI have been published [<a class="bk_pop" href="#oi.REF.ben_amor.2011.540178">Ben Amor et al 2011</a>], but there are exceptions to these rules (e.g., glycine to serine substitutions may lead to a more severe phenotype in <i>COL1A1</i> than a similar change in <i>COL1A2</i>). The extent of variation and the clinical presentation is represented in <a class="bk_pop" href="#oi.REF.maioli.2019.1090">Maioli et al [2019]</a> (see Figure 2).</p></div><div id="oi.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>It is important to keep the exceptions in mind when providing <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>, particularly in the prenatal setting. Genotyping can be helpful in distinguishing classic non-deforming OI from all other types of OI.</p><p><b>Classic non-deforming OI</b> almost always results from a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one <i>COL1A1</i> or <i>COL1A2</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> that introduces premature termination codons and decreases the stability of <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> (<a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>-mediated decay of the message resulting in a quantitative reduction of the collagen fibril). These causative variants may occur by codon changes, by frame shifts, and by <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> that results in use of cryptic splice sites and premature termination. The type I collagen molecule contains two pro &#x003b1;1(I) chains and a single &#x003b1;2(I) chain. If the number of available pro &#x003b1;1(I) chains decreases, the amount of the trimer manufactured is diminished because no more than one pro &#x003b1;2(I) chain can be accommodated per molecule.</p><p><b>Perinatally lethal OI, progressively deforming OI, and common variable OI</b> all result from pathogenic variants that alter the structure of either pro &#x003b1;1(I) or pro &#x003b1;2(I) chains. This causes a <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> effect whereby the abnormal protein is integrated into the triple helix and collagen fibril, which in turn undergoes continual remodeling, thus resulting in significantly compromised structural integrity of the bone matrix (a qualitative impact on the protein product).</p><p>The most common pathogenic variants result in substitution of another amino acid for glycine in the triple helical <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of either chain; serine, arginine, cysteine, and tryptophan result from substitutions in the first position of the glycine codon and alanine, valine, glutamic acid, and aspartic acid result from substitutions in the second position of the glycine codon. Glycine is the least bulky amino acid, and other substituting amino acids do not fit well into the collagen triple helix.</p><ul><li class="half_rhythm"><div>Substitutions in the pro &#x003b1;1(I) chain by arginine, valine, glutamic acid, aspartic acid, and tryptophan are almost always lethal if they occur in the carboxyl-terminal 70% of the triple helix and have a non-lethal but still moderately severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> if they occur in the remainder of the chain.</div></li><li class="half_rhythm"><div>For the smaller side-chain residues (serine, alanine, and cysteine), the phenotypes are more variable and appear to reflect some characteristics of the stability profile of the triple helix that are not yet fully recognized.</div></li><li class="half_rhythm"><div>Much more variability occurs with pathogenic variants that affect glycine residues in the pro &#x003b1;2(I) chain, even with the large side-chain residues; therefore, it is more difficult to determine the <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> relationship.</div></li></ul><p>The other common disease-causing variants affect splice sites. Variants that lead to <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> skipping in the pro &#x003b1;1(I) chain beyond exon 14 and in the pro &#x003b1;2(I) chain beyond exon 25 are generally lethal. The phenotypes resulting from pathogenic variants in the upstream region are more variable and may lead to significant joint hypermobility.</p><p>A relatively small number of pathogenic variants that alter amino acid sequences in the carboxyl-terminal regions of both chains have been identified. These domains are used for chain association and pathogenic variants have the capacity to destroy this property or lead to abnormalities in chain association. The phenotypic effects of pathogenic variants that affect this <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> appear to be milder when they result in exclusion rather than inclusion of the chain.</p><p><b>Somatic <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a></b> for dominant pathogenic variants has been recognized in perinatally lethal OI, progressively deforming OI, and common variable OI. The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of the individual with <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> can range from no identifiable characteristics of OI to one of the mild forms. The current estimate for the incidence of somatic/<a class="def" href="/books/n/gene/glossary/def-item/gonadal-mosaicism/">gonadal mosaicism</a> is up to 16% of families.</p><ul><li class="half_rhythm"><div>Individuals with <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for variants that result in non-lethal forms of OI generally have no phenotypic features of OI, even when the variant is present in a majority of somatic cells.</div></li><li class="half_rhythm"><div>Somatic <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> for variants that result in lethal OI can produce a mild OI <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> if the variant is present in the majority of somatic cells; otherwise, the mosaicism is generally asymptomatic.</div></li></ul></div><div id="oi.Penetrance"><h3>Penetrance</h3><p>The <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in individuals <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>COL1A1</i> or <i>COL1A2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is 100%, although expression may vary considerably, even in the same family.</p></div><div id="oi.Nomenclature"><h3>Nomenclature</h3><p>Current (and previously used) nomenclature:</p><ul><li class="half_rhythm"><div>Classic non-deforming OI with blue sclerae (previously, osteogenesis imperfecta type I)</div></li><li class="half_rhythm"><div>Perinatally lethal OI (osteogenesis imperfecta type II)</div></li><li class="half_rhythm"><div>Progressively deforming OI (osteogenesis type III)</div></li><li class="half_rhythm"><div>Common variable OI with normal sclerae (osteogenesis imperfecta type IV)</div></li></ul><p>The classification scheme of "OI congenita" and "OI tarda" was discarded because fractures at birth can be noted in mild OI and infants with severe OI may not have fractures at birth.</p><p>In classifications of genetic conditions, OI may be considered a skeletal dysplasia, a connective tissue disorder, a disorder of collagen or extracellular matrix, or a disorder of bone fragility.</p></div><div id="oi.Prevalence"><h3>Prevalence</h3><p>Considering all types, OI has a prevalence of approximately 6-7:100,000. <i>COL1A1/2</i>-OI comprises the largest proportion of OI, representing about 90% of all causes of OI.</p></div></div><div id="oi.Genetically_Related_Allelic_Disorders"><h2 id="_oi_Genetically_Related_Allelic_Disorders_">Genetically Related (Allelic) Disorders</h2><p>Other phenotypes associated with <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>COL1A1</i> and <i>COL1A2</i> are summarized in <a class="figpopup" href="/books/NBK1295/table/oi.T.allelic_disorders/?report=objectonly" target="object" rid-figpopup="figoiTallelicdisorders" rid-ob="figoboiTallelicdisorders">Table 4</a>.</p><div id="oi.T.allelic_disorders" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Allelic Disorders</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1295/table/oi.T.allelic_disorders/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__oi.T.allelic_disorders_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_oi.T.allelic_disorders_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_oi.T.allelic_disorders_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_oi.T.allelic_disorders_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference</th></tr></thead><tbody><tr><td headers="hd_h_oi.T.allelic_disorders_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>COL1A1</i></td><td headers="hd_h_oi.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Caffey disease (infantile cortical hyperostosis)</td><td headers="hd_h_oi.T.allelic_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/caffey/">Caffey Disease</a></td></tr><tr><td headers="hd_h_oi.T.allelic_disorders_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Classic Ehlers-Danlos syndrome&#x000a0;<sup>1</sup></td><td headers="hd_h_oi.T.allelic_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/eds/">Classic Ehlers-Danlos Syndrome</a></td></tr><tr><td headers="hd_h_oi.T.allelic_disorders_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Osteoporosis&#x000a0;<sup>2</sup></td><td headers="hd_h_oi.T.allelic_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OMIM <a href="https://omim.org/entry/166710" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">166710</a></td></tr><tr><td headers="hd_h_oi.T.allelic_disorders_1_1_1_2" rowspan="2" colspan="1" scope="row" style="text-align:left;vertical-align:middle;">Arthrochalasia Ehlers-Danlos syndrome&#x000a0;<sup>3</sup></td><td headers="hd_h_oi.T.allelic_disorders_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">OMIM <a href="https://omim.org/entry/130060" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">130060</a></td></tr><tr><td headers="hd_h_oi.T.allelic_disorders_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><i>COL1A2</i></td></tr><tr><td headers="hd_h_oi.T.allelic_disorders_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Cardiac-valvular Ehlers-Danlos syndrome&#x000a0;<sup>4</sup></td><td headers="hd_h_oi.T.allelic_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OMIM <a href="https://omim.org/entry/225320" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">225320</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="oi.TF.4.1"><p class="no_margin">&#x0003c;1% of classic Ehlers-Danlos syndrome is attributed to pathogenic variants in <i>COL1A1</i>. Although most pathogenic variants in <i>COL1A1</i> cause osteogenesis imperfecta, specific <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants have been associated with specific Ehlers-Danlos syndrome subtypes (see <a href="/books/n/gene/eds/">Classic Ehlers-Danlos Syndrome</a>, Molecular Genetics).</p></div></dd><dt>2. </dt><dd><div id="oi.TF.4.2"><p class="no_margin">The common variant Sp1 (c.104-144G&#x0003e;T; <a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000088.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000088<wbr style="display:inline-block"></wbr>​.3</a>) in <i>COL1A1</i> has been shown to affect bone mineral density and quality, predisposing to osteoporotic fractures, particularly of the vertebrae.</p></div></dd><dt>3. </dt><dd><div id="oi.TF.4.3"><p class="no_margin">Affected individuals have <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> bilateral hip dislocation, short stature, joint hypermobility, osteopenia, kyphoscoliosis, velvety hyperextensible skin, and mild bone fragility. The arthrochalasia form of Ehlers-Danlos syndrome results from loss of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 6 of either <i>COL1A1</i> or <i>COL1A2</i>.</p></div></dd><dt>4. </dt><dd><div id="oi.TF.4.4"><p class="no_margin">The cardiac-valvular form of Ehlers-Danlos syndrome results from <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>COL1A2</i> pathogenic variants.</p></div></dd></dl></div></div></div><p><b>Arterial dissection.</b> Published evidence to date does not support a clear association between spontaneous arterial rupture and <i>COL1A1/2</i> variants. A study investigating the histopathologic changes in spontaneous carotid artery dissection (sCAD) concluded that no unique connective tissue or vascular <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> existed in individuals with a known connective tissue disorder when compared to control subjects with ischemic stroke of other etiologies [<a class="bk_pop" href="#oi.REF.dittrich.2007.2120">Dittrich et al 2007</a>].</p><p>There have been several isolated case reports of individuals with an identified <i>COL1A1</i> variant who have suffered spontaneous arterial rupture. <a class="bk_pop" href="#oi.REF.mayer.1996.552">Mayer et al [1996]</a> described a G-to-C transversion in one <i>COL1A1</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> resulting in a Gly13Ala substitution in the triple helical <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of the pro &#x003b1;1(I) chain of type I collagen in a woman age 35 years with dissection of the right internal carotid artery and the right vertebral artery after scuba diving. Other than a history of easy bruising and bluish sclerae, she had no evidence of a connective tissue disorder or of OI. Her family history was negative for other individuals with vasculopathy. <a class="bk_pop" href="#oi.REF.malfait.2007.387">Malfait et al [2007]</a> describe three unrelated individuals with arginine-to-cysteine substitutions in the pro &#x003b1;1(I) chain who developed iliac or femoral dissection in early adulthood and also had symptoms of classic EDS and osteopenia.</p><p>See also Clinical Description, <a href="#oi.Other_Considerations">Other Considerations</a>, <b>Cardiovascular</b> for details relating to aortic root dilatation and dissection.</p></div><div id="oi.Differential_Diagnosis"><h2 id="_oi_Differential_Diagnosis_">Differential Diagnosis</h2><div id="oi.Distinguishing_COL1A12_Osteogenesis_I"><h3>Distinguishing <i>COL1A1/2</i> Osteogenesis Imperfecta (<i>COL1A1/2</i>-OI) from Other Types of OI</h3><p>The primary differential diagnoses for individuals with features of <i>COL1A1/2</i>-OI are non-collagen-associated forms of OI. There are both dominant and recessive types, which can be phenotypically indistinct from <i>COL1A1/2-</i>OI. In a small subset of individuals, specific causative variants have not yet been identified. <a class="figpopup" href="/books/NBK1295/table/oi.T.other_types_of_osteogenesis_imperfe/?report=objectonly" target="object" rid-figpopup="figoiTothertypesofosteogenesisimperfe" rid-ob="figoboiTothertypesofosteogenesisimperfe">Table 5</a> summarizes the molecular basis of these subtypes of OI, the <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>, the corresponding clinical OI type, and distinguishing clinical and radiographic features.</p><div id="oi.T.other_types_of_osteogenesis_imperfe" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Other Types of Osteogenesis Imperfecta in the Differential Diagnosis of <i>COL1A1/2</i> Osteogenesis Imperfecta</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1295/table/oi.T.other_types_of_osteogenesis_imperfe/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__oi.T.other_types_of_osteogenesis_imperfe_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Functional Group</th><th id="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OMIM-Defined Genetic OI Type&#x000a0;<sup>1</sup></th><th id="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical OI<br />Type&#x000a0;<sup>2</sup></th><th id="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from <i>COL1A1/2</i>-OI</th></tr></thead><tbody><tr><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_1" rowspan="10" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Collagen type I processing</b></td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>BMP1</i></td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI type XIII (OMIM <a href="https://omim.org/entry/614856" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">614856</a>)</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI-III</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Umbilical hernia; hypertelorism; no DI or HL</td></tr><tr><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>CRTAP</i></td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI type VII (OMIM <a href="https://omim.org/entry/610682" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">610682</a>)</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI-II, III, or IV</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal birth length; proptosis; no DI; pulmonary vasculature malformations; rhizomelia</td></tr><tr><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>FKBP10</i></td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bruck syndrome 1 / OI type XI (OMIM <a href="https://omim.org/entry/259450" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">259450</a> &#x00026; <a href="https://omim.org/entry/610968" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">610968</a>)</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI-III or IV</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Brachycephaly; no easy bruising; no DI or HL; white sclera; inguinal hernia; joint contractures; pterygia</td></tr><tr><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>P3H1</i> (<i>LEPRE1</i>)</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI type VIII (OMIM <a href="https://omim.org/entry/610915" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">610915</a>)</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI-II or III</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No DI; white sclerae; proptosis; long phalanges</td></tr><tr><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>PLOD2</i></td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bruck syndrome 2 (OMIM <a href="https://omim.org/entry/609220" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">609220</a>)</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI-III</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No DI or HL; white sclerae; inguinal hernia; joint contractures; pterygia</td></tr><tr><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>PPIB</i></td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI type IX (OMIM <a href="https://omim.org/entry/259440" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">259440</a>)</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI-II, III, or IV</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No DI or HL; white sclerae</td></tr><tr><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>SEC24D</i></td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cole-Carpenter syndrome 2 (OMIM <a href="https://omim.org/entry/616294" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">616294</a>)</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI-III</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Turricephaly; proptosis; hypertelorism; dysplastic ears; no HL; white sclerae; hydrocephalus; high-pitched voice</td></tr><tr><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>SERPINH1</i></td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI type X (OMIM <a href="https://omim.org/entry/613848" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613848</a>)</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI-III</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Macrocephaly; proptosis; renal calculi</td></tr><tr><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>SPARC</i></td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI type XVII (OMIM <a href="https://omim.org/entry/616507" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">616507</a>)</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI-IV</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No DI or HL; white sclerae; risk for intracranial hemorrhage</td></tr><tr><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>TMEM38B</i></td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI type XIV (OMIM <a href="https://omim.org/entry/615066" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615066</a>)</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI-III</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No DI or HL; white sclerae</td></tr><tr><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_1" rowspan="8" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Other osteoblast genes</b></td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CREB3L1</i></td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI type XVI (OMIM <a href="https://omim.org/entry/616229" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">616229</a>)</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI-III</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Tooth agenesis</td></tr><tr><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>IFITM5</i></td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI w/calcification in interosseous membranes, OI type V (OMIM <a href="https://omim.org/entry/610967" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">610967</a>)</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Short stature &#x00026; fractures</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sclerae generally white; DI rare; hypertrophic callus formation; calcification of interosseous membrane between ulna &#x00026; radius that leads to inability to fully supinate &#x00026; pronate forearm; no HL</td></tr><tr><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>MBTPS2</i></td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI type XIX (OMIM <a href="https://omim.org/entry/301014" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">301014</a>)</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI-III or IV</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No HL; sclerae generally white; rhizomelia; epiphyseal "popcorn" calcification</td></tr><tr><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>MESD</i>&#x000a0;<sup>3</sup></td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI type XX (OMIM <a href="https://omim.org/entry/618644" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">618644</a>)</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI-III-IV</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Facial dysmorphisms incl arched eyebrows &#x00026; tented shape of lips; long fingers w/5<sup>th</sup> finger camptodactyly; oligodontia</td></tr><tr><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>SERPINF1</i></td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI type VI (OMIM <a href="https://omim.org/entry/613982" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613982</a>)</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI-III or IV</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No DI or HL</td></tr><tr><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>SP7</i></td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI type XII (OMIM <a href="https://omim.org/entry/613849" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613849</a>)</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI-III or IV</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No DI; white sclerae</td></tr><tr><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>TENT5A</i> (<i>FAM46A</i>)</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI type XVIII (OMIM <a href="https://omim.org/entry/617952" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">617952</a>)</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI-III or IV</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No DI or HL; umbilical hernia</td></tr><tr><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>WNT1</i></td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI type XV (OMIM <a href="https://omim.org/entry/615220" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615220</a>)</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OI-III or IV</td><td headers="hd_h_oi.T.other_types_of_osteogenesis_imperfe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Structural brain malformations; rhizomelia</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; DI = dentinogenesis imperfecta; HL = hearing loss; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd><dt>1. </dt><dd><div id="oi.TF.5.1"><p class="no_margin">See OMIM: <a href="https://omim.org/clinicalSynopsis/table?mimNumber=610915,610682,616507,617952,166220,166210,259420,614856,615066,610967,616229,613848,615220,613849,259440,613982,610968,166220,166210,166200,259420,301014,609220,259450,112240,616294,613982,616507,615066" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Clinical Synopsis Table</a>.</p></div></dd><dt>2. </dt><dd><div id="oi.TF.5.2"><p class="no_margin"><a class="bk_pop" href="#oi.REF.bonafe.2015.2869">Bonafe et al [2015]</a>, <a class="bk_pop" href="#oi.REF.robinson.2019.11">Robinson &#x00026; Rauch [2019]</a></p></div></dd><dt>3. </dt><dd><div id="oi.TF.5.3"><p class="no_margin"><a class="bk_pop" href="#oi.REF.moosa.2019.836">Moosa et al [2019]</a></p></div></dd></dl></div></div></div></div><div id="oi.Distinguishing_OI_from_Other_Disorder"><h3>Distinguishing OI from Other Disorders and Non-Accidental Trauma</h3><p>The differential diagnosis of OI depends largely on the age at which the individual is assessed [<a class="bk_pop" href="#oi.REF.plotkin.2004.16">Plotkin 2004</a>]. Clinical features that help to differentiate <i>COL1A1/2</i>-OI from other conditions include characteristic triangular facies, blue sclerae, joint hypermobility, dental abnormalities, and, in adults, hearing loss.</p><div id="oi.In_Utero_Assessment"><h4>In Utero Assessment</h4><p>Early prenatal ultrasound examination or radiographic findings may lead to a consideration of <a href="/books/n/gene/hops/">hypophosphatasia</a>, <a href="/books/n/gene/td/">thanatophoric dysplasia</a>, <a href="/books/n/gene/campo-dysp/">campomelic dysplasia</a>, and <a href="/books/n/gene/achon1b/">achondrogenesis</a> as well as perinatally lethal OI. In some cases, either biochemical or molecular testing can be a useful adjunct.</p><div id="oi.T.genes_of_interest_in_the_differenti" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p>Genes of Interest in the Differential Diagnosis of <i>COL1A1/2</i> Osteogenesis Imperfecta &#x02013; In Utero Assessment</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1295/table/oi.T.genes_of_interest_in_the_differenti/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__oi.T.genes_of_interest_in_the_differenti_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_2" style="text-align:left;vertical-align:middle;">Differential<br />Diagnosis<br />Disorder&#x000a0;<sup>1</sup></th><th id="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Prenatal Ultrasound &#x00026; Radiographic Findings in Differential Diagnosis Disorder</th></tr><tr><th headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_4" id="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/<i>COL1A1/2</i>-OI</th><th headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_4" id="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not observed in <i>COL1A1/2</i>-OI</th></tr></thead><tbody><tr><td headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ALPL</i></td><td headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/hops/">Perinatal hypophosphatasia</a></td><td headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_4 hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Blue sclerae; abnormal teeth; fractures</td><td headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_4 hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rickets; GI: poor feeding, emesis; craniosynostosis; vertebral clefts; low alkaline phosphatase; high calcium in serum &#x00026; urine; bone spurs</td></tr><tr><td headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FGFR3</i></td><td headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/td/">Thanatophoric dysplasia</a></td><td headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_4 hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In severe OI: fetal hydrops &#x00026; respiratory distress</td><td headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_4 hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe micromelia; cloverleaf skull; small iliac bones, narrow sacroiliac notch</td></tr><tr><td headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLC26A2</i></td><td headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/achon1b/">Achondrogenesis type 1B</a></td><td headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_4 hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Thin short ribs in severe OI</td><td headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_4 hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absent mineralization; severe micromelia</td></tr><tr><td headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SOX9</i></td><td headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/campo-dysp/">Campomelic dysplasia</a></td><td headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_4 hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Respiratory distress in severe OI; short limbs &#x00026; small chest</td><td headers="hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_1_4 hd_h_oi.T.genes_of_interest_in_the_differenti_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Curved femurs w/skin dimpling; absent/hypoplastic scapula; macrocephaly; large anterior fontanelle; male sex reversal (46XY, female); undermineralized thoracic vertebral pedicles; <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> heart defect</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a></p></div></dd><dt>1. </dt><dd><div id="oi.TF.6.1"><p class="no_margin">See OMIM: <a href="https://omim.org/clinicalSynopsis/table?mimNumber=166210,600972,200610,200600,114290,187600,187601,241500" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Clinical Synopsis Table</a>.</p></div></dd></dl></div></div></div></div><div id="oi.Infancy_and_Childhood_Assessment"><h4>Infancy and Childhood Assessment</h4><p><b>Non-accidental trauma (NAT; child abuse).</b>
<i>COL1A1/2</i>-OI needs to be distinguished from child physical abuse / non-accidental trauma. The prevalence of physical abuse is much greater than the prevalence of <i>COL1A1/2</i>-OI, and on rare occasion, it can occur in a child with <i>COL1A1/2</i>-OI. Patient history, family history, physical examination, radiographic imaging, and the clinical course all contribute to distinguishing <i>COL1A1/2</i>-OI from child abuse. The overlap in clinical features includes multiple or recurrent fractures, fractures that do not match the history of trauma, and the finding of fractures of varying ages and at different stages of healing [<a class="bk_pop" href="#oi.REF.carty.1988.350">Carty 1988</a>, <a class="bk_pop" href="#oi.REF.ablin.1990.1035">Ablin et al 1990</a>, <a class="bk_pop" href="#oi.REF.steiner.1996.542">Steiner et al 1996</a>, <a class="bk_pop" href="#oi.REF.ablin.1997.111">Ablin &#x00026; Sane 1997</a>, <a class="bk_pop" href="#oi.REF.marlowe.2002.382">Marlowe et al 2002</a>].</p><p>The continued occurrence of fractures in a child who has been removed from a possibly abusive situation lends support to the possibility of <i>COL1A1/2</i>-OI. Metaphyseal and rib fractures, thought to be virtually pathognomonic for child abuse, can rarely occur in <i>COL1A1/2</i>-OI. The presence or absence of blue sclerae is unreliable in distinguishing <i>COL1A1/2</i>-OI from child abuse because blue sclerae are often found in unaffected normal infants until about age 18 months; children with OI type IV may not have blue sclerae.</p><p>Family history is often unrevealing; families suspected of possible child abuse often provide an unverified family history of frequent fractures; conversely, the family history of individuals with <i>COL1A1/2</i>-OI often does not reveal any other <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals because of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> or the presence of a mild <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in relatives.</p><p>Laboratory testing (typically <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>COL1A1</i> and <i>COL1A2</i>) usually is not needed to differentiate <i>COL1A1/2</i>-OI from NAT, and in some cases, the time required to perform such testing can delay proper disposition of child abuse cases [<a class="bk_pop" href="#oi.REF.steiner.1996.542">Steiner et al 1996</a>]. Marlowe and colleagues suggest: "Given the inability to identify all children with OI by clinical examination in situations of suspected non-accidental injury, laboratory testing for OI (and other genetic predispositions for fractures) is a valuable adjunct in discerning the basis for fractures and may identify a small group of children with previously undiagnosed OI" [<a class="bk_pop" href="#oi.REF.marlowe.2002.382">Marlowe et al 2002</a>]. Laboratory testing in such cases is no substitute for proper clinical evaluation that includes history, family history, physical examination, and radiographic evaluation.</p><p><b>Other genetic disorders.</b> See <a class="figpopup" href="/books/NBK1295/table/oi.T.other_genetic_disorders_of_interest/?report=objectonly" target="object" rid-figpopup="figoiTothergeneticdisordersofinterest" rid-ob="figoboiTothergeneticdisordersofinterest">Table 7</a>.</p><div id="oi.T.other_genetic_disorders_of_interest" class="table"><h3><span class="label">Table 7. </span></h3><div class="caption"><p>Other Genetic Disorders of Interest in the Differential Diagnosis of <i>COL1A1/2</i> Osteogenesis Imperfecta</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1295/table/oi.T.other_genetic_disorders_of_interest/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__oi.T.other_genetic_disorders_of_interest_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_2" style="text-align:left;vertical-align:middle;">Differential<br />Diagnosis<br />Disorder&#x000a0;<sup>1</sup></th><th id="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Clinical Features of the Differential Diagnosis Disorder</th></tr><tr><th headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_4" id="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/<i>COL1A1/2</i>-OI</th><th headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_4" id="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not observed in <i>COL1A1/2</i>-OI</th></tr></thead><tbody><tr><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ANO5</i></td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gnathodiaphyseal dysplasia (OMIM <a href="http://omim.org/entry/166260" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">166260</a>)</td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_4 hd_h_oi.T.other_genetic_disorders_of_interest_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Osteopenia &#x00026; bone fragility</td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_4 hd_h_oi.T.other_genetic_disorders_of_interest_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Enlarged jaw; osteomyelitis</td></tr><tr><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>DSPP</i></td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dentinogenesis imperfecta (OMIM <a href="https://omim.org/entry/125490" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">125490</a>)</td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_4 hd_h_oi.T.other_genetic_disorders_of_interest_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DI</td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_4 hd_h_oi.T.other_genetic_disorders_of_interest_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Primary teeth more impacted than secondary teeth</td></tr><tr><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GORAB</i></td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gerodermia osteodysplastica (OMIM <a href="http://omim.org/entry/231070" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">231070</a>)</td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_4 hd_h_oi.T.other_genetic_disorders_of_interest_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Osteopenia &#x00026; bone fragility</td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_4 hd_h_oi.T.other_genetic_disorders_of_interest_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Microcephaly; premature aged facial appearance; camptodactyly; intellectual disability</td></tr><tr><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>LRP5</i></td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Osteoporosis pseudoglioma syndrome (OMIM <a href="http://omim.org/entry/259770" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">259770</a>)</td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_4 hd_h_oi.T.other_genetic_disorders_of_interest_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Osteopenia &#x00026; bone fragility</td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_4 hd_h_oi.T.other_genetic_disorders_of_interest_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Microcephaly; pseudoglioma; cataracts; blindness; <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> heart defect</td></tr><tr><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>NOTCH2</i></td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hadju-Cheney syndrome (OMIM <a href="http://omim.org/entry/102500" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">102500</a>)</td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_4 hd_h_oi.T.other_genetic_disorders_of_interest_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Osteopenia &#x00026; bone fragility</td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_4 hd_h_oi.T.other_genetic_disorders_of_interest_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Coarse facial appearance; early tooth loss; <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> heart defect; male hypospadias/cryptorchidism; renal cysts</td></tr><tr><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>P4HB</i></td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cole-Carpenter syndrome 1 (OMIM <a href="http://omim.org/entry/112240" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">112240</a>)</td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_4 hd_h_oi.T.other_genetic_disorders_of_interest_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Enamel hypoplasia; osteopenia &#x00026; fractures</td><td headers="hd_h_oi.T.other_genetic_disorders_of_interest_1_1_1_4 hd_h_oi.T.other_genetic_disorders_of_interest_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Midface hypoplasia; frontal bossing; proptosis; pseudoclubbing; acroosteolysis</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a></p></div></dd><dt>1. </dt><dd><div id="oi.TF.7.1"><p class="no_margin">See OMIM: <a href="https://omim.org/clinicalSynopsis/table?mimNumber=166210,166260,125490,259450,231070,259770,102500,112240" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Clinical Synopsis Table</a>.</p></div></dd></dl></div></div></div><p><b>Idiopathic juvenile osteoporosis</b> (OMIM <a href="https://omim.org/entry/259750" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">259750</a>) typically presents in pre-adolescents with fractures and osteoporosis. The fracture susceptibility and osteoporosis usually resolve spontaneously with puberty.</p></div></div></div><div id="oi.Management"><h2 id="_oi_Management_">Management</h2><div id="oi.Evaluations_Following_Initial_Diagnos"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual diagnosed with <i>COL1A1/2</i> osteogenesis imperfecta (<i>COL1A1/2</i>-OI), the evaluations summarized in <a class="figpopup" href="/books/NBK1295/table/oi.T.recommended_evaluations_following_i/?report=objectonly" target="object" rid-figpopup="figoiTrecommendedevaluationsfollowingi" rid-ob="figoboiTrecommendedevaluationsfollowingi">Table 8</a> (if not performed as part of the evaluation that led to the diagnosis) are recommended.</p><div id="oi.T.recommended_evaluations_following_i" class="table"><h3><span class="label">Table 8. </span></h3><div class="caption"><p>Recommended Evaluations Following Initial Diagnosis in Individuals with <i>COL1A1/2</i> Osteogenesis Imperfecta</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1295/table/oi.T.recommended_evaluations_following_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__oi.T.recommended_evaluations_following_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_oi.T.recommended_evaluations_following_i_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_oi.T.recommended_evaluations_following_i_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_oi.T.recommended_evaluations_following_i_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_oi.T.recommended_evaluations_following_i_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Musculoskeletal</b></td><td headers="hd_h_oi.T.recommended_evaluations_following_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Physical examination</td><td headers="hd_h_oi.T.recommended_evaluations_following_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To assess deformities &#x00026; presence of joint laxity</td></tr><tr><td headers="hd_h_oi.T.recommended_evaluations_following_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Referral to PT &#x00026; OT</div></li><li class="half_rhythm"><div>Surgical intervention as needed through experienced orthopedic management</div></li></ul>
</td><td headers="hd_h_oi.T.recommended_evaluations_following_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">As indicated by clinical presentation</td></tr><tr><td headers="hd_h_oi.T.recommended_evaluations_following_i_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_oi.T.recommended_evaluations_following_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CT &#x00026;/or MRI examination w/views across base of skull to evaluate for basilar impression</td><td headers="hd_h_oi.T.recommended_evaluations_following_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">If concerning signs or symptoms are present&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_oi.T.recommended_evaluations_following_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Cervical spine flexion &#x00026; extension radiographs</td><td headers="hd_h_oi.T.recommended_evaluations_following_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In children able to cooperate w/examination or before participating in sporting activities in more mildly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals</td></tr><tr><td headers="hd_h_oi.T.recommended_evaluations_following_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Dental</b></td><td headers="hd_h_oi.T.recommended_evaluations_following_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dental examination</td><td headers="hd_h_oi.T.recommended_evaluations_following_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>When teeth erupt in those w/DI or at risk for DI</div></li><li class="half_rhythm"><div>By age 2-3 yrs for all children w/OI</div></li></ul>
</td></tr><tr><td headers="hd_h_oi.T.recommended_evaluations_following_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Audiologic</b></td><td headers="hd_h_oi.T.recommended_evaluations_following_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Formal hearing assessment</td><td headers="hd_h_oi.T.recommended_evaluations_following_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In all individuals at diagnosis</td></tr><tr><td headers="hd_h_oi.T.recommended_evaluations_following_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Other</b></td><td headers="hd_h_oi.T.recommended_evaluations_following_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consultation w/clinical geneticist &#x00026;/or genetic counselor</td><td headers="hd_h_oi.T.recommended_evaluations_following_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">DI = dentinogenesis imperfecta; OT = occupational therapist; PT = physical therapist</p></div></dd><dt>1. </dt><dd><div id="oi.TF.8.1"><p class="no_margin">There is no universal agreement on when screening for basilar impression should be performed. A positive "Lhermitte's sign" (tingling in fingers with neck flexion) should prompt neurosurgical referral. Surgery is typically undertaken before persistent/permanent neurologic features are present.</p></div></dd></dl></div></div></div></div><div id="oi.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Management focuses on supportive therapy to minimize fractures and maximize function, minimize disability, foster independence, and maintain overall health [<a class="bk_pop" href="#oi.REF.marini.1997.746">Marini &#x00026; Gerber 1997</a>]. Ideally, <i>COL1A1/2</i>-OI is managed by a multidisciplinary team including specialists in the medical management of <i>COL1A1/2</i>-OI, clinical genetics, orthopedics, rehabilitation medicine, pediatric dentistry, otology/otolaryngology, and mental health.</p><p>Supportive therapy is individualized depending on the severity, degree of impairment, and age of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual. Considerable support from medical personnel is generally required by parents caring for infants with perinatally lethal <i>COL1A1/2</i>-OI.</p><p><b>Physical medicine treatment</b></p><ul><li class="half_rhythm"><div>Parents and other caregivers should be instructed in safe handling techniques. These are mostly commonsense practices in order to relieve stress on a single point. For example: lift an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> infant by bracing the torso, neck, and lower body; avoid any situation where increased pressure is placed on a single point on any long bone; when assisting an affected child in standing up, do not pull excessively on an extended arm but bend down and brace a greater surface area (e.g., placing a hand behind the back and pulling gently from the front &#x02013; using the arm &#x02013; while applying pressure from the rear); avoid sudden acceleration/deceleration movements; and avoid throwing a child in the air. To minimize point pressure, avoid lifting an infant by the ankle when diapering. Older children should not ride on amusement park rides. Caregivers should avoid re-creating the circumstances of a fracture, as it is likely to happen again.</div></li><li class="half_rhythm"><div>The use of bracing to try to stabilize progressively deforming limbs depends in part on the subtype of <i>COL1A1/2</i>-OI. Progressively deforming OI has proven to be progressive despite external or internal bracing. The use of internal rods or braces to support and stabilize deforming limbs is more successful in the milder subtypes of <i>COL1A1/2</i>-OI and is guided by the expertise of the managing orthopedist.</div></li><li class="half_rhythm"><div>Orthotics to support ankle instability are used in toddlers with delayed walking secondary to joint hypermobility and in other <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals who suffer recurrent subluxations of their ankle joints.</div></li><li class="half_rhythm"><div>Physical activity serves a number of purposes. It provides gravitational stressors required for bone growth and remodeling. The muscles' supporting joints are strengthened by activity, and as an overall benefit, improved joint stability aids in overall well-being as pain levels are reduced and mobility is increased. Physical activity can be self directed or coordinated through the services of a physical therapist. Each <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual's needs are unique and thus both physical and occupational therapy should be initiated for increased stability of bone, improved mobility, prevention of contractures, prevention of head and spinal deformity, and improved aerobic fitness and muscle strengthening.</div></li><li class="half_rhythm"><div>Mobility devices, such as scooters and chairs for children and modified automobiles for adults, should be considered.</div></li><li class="half_rhythm"><div>Some individuals with <i>COL1A1/2</i>-OI experience chronic daily pain associated with both fractures and nonspecific myofascial pain associated with the generalized connective tissue disorder. Pain management plays an important role in the management of <i>COL1A1/2</i>-OI. Some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals do well with minimal analgesics, but many benefit from a multidisciplinary pain management service. Analgesics can be used to control pain from fractures.</div></li></ul><p><b>Orthopedic treatment.</b> Fractures are treated as they would be in unaffected children and adults with attention to the following:</p><ul><li class="half_rhythm"><div>The period of immobility in children with <i>COL1A1/2</i>-OI should be shortened as much as is practical.</div></li><li class="half_rhythm"><div>Casts should be small and lightweight.</div></li><li class="half_rhythm"><div>Physical therapy should begin as soon as the cast is removed to promote mobility and enhance muscle strength and bone mass.</div></li><li class="half_rhythm"><div>At this time, intramedullary rodding remains a mainstay of orthopedic care to provide anatomic positioning of limbs to permit more normal function.</div></li></ul><p>Progressive spinal deformities are particularly difficult to treat because of the poor quality of bone in severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children. Progressive scoliosis in severe <i>COL1A1/2</i>-OI may not respond well to conservative management and response to surgical intervention may be limited.</p><p><b>Pharmacologic treatment.</b> Bisphosphonates, analogs of pyrophosphate that decrease bone resorption, are being evaluated in both uncontrolled and controlled trials to assess the extent to which they can increase bone mass and bone strength and improve function in children with <i>COL1A1/2</i>-OI. These studies are still ongoing. Bisphosphonates have been used most extensively in severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children; they may be useful in adults as well [<a class="bk_pop" href="#oi.REF.adami.2003.126">Adami et al 2003</a>].</p><p>The role of treatment with bisphosphonates in changing the natural history of <i>COL1A1/2</i>-OI is incompletely understood. The Cochrane Collaboration is an international network that assembles reviews on various management strategies based on randomized controlled clinical trials within its database in order to improve the practice of evidence-based medicine. As of the Cochrane Collaboration's most recent update of the OI review, bisphosphonate therapy did not appear to reduce fracture incidence but it did affect bone density and adult height [<a class="bk_pop" href="#oi.REF.dwan.2014.cd005088">Dwan et al 2014</a>] (<a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005088.pub3/abstract;jsessionid=7EE4AB309EAD68F22BE8C7C5554CDE12.f02t02" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>).</p><p>In a more recent publication <a class="bk_pop" href="#oi.REF.bains.2019.e10118">Bains et al [2019]</a> collated data from the Osteogenesis Imperfecta Foundation's linked clinical research centers on 466 patients with all forms of OI who had been treated with bisphosphonates. The review of the data primarily focused on classic non-deforming OI with blue sclerae (type I). Primary findings indicated increased lumbar vertebral body density, and statistical regression analysis indicated reduced probability of fracture and scoliosis in individuals treated with bisphosphonates compared with those untreated.</p><p>Pamidronate use is invasive and typically requires intravenous infusions every three months, four hours a day, for three days. Pamidronate has been used to treat newborn infants with severe OI; complications include transient asymptomatic hypocalcemia [<a class="bk_pop" href="#oi.REF.plotkin.2000.1846">Plotkin et al 2000</a>] and symptomatic hypocalcemia [<a class="bk_pop" href="#oi.REF.chien.2002.593">Chien et al 2002</a>]. The long-term consequences of lowering bone turnover in children with <i>COL1A1/2</i>-OI are unknown but may include delayed bone union after fracture or osteotomy.</p><p>A randomized controlled clinical trial using the oral bisphosphonate alendronate found that treatment with oral alendronate for two years in children with OI significantly decreased bone turnover and increased spine areal BMD (bone mineral content measured by DEXA divided by bone area in square centimeters) but was not associated with improved fracture outcomes [<a class="bk_pop" href="#oi.REF.ward.2011.355">Ward et al 2011</a>]. In a second study with a different oral bisphosphonate, Bishop and colleagues found that oral risedronate increased areal BMD and reduced first and recurrent clinical fractures in children with OI [<a class="bk_pop" href="#oi.REF.bishop.2010.32">Bishop et al 2010</a>]. Zoledronic acid, a bisphosphonate with a longer half-life, greater potency, and more convenient dosing, has been studied in children with OI. <a class="bk_pop" href="#oi.REF.lv.2018.179">Lv et al [2018]</a> compared the efficacy of an annual infusion of zoledronic acid to weekly oral alendronate and concluded that these treatment approaches had similar increases in vertebral BMD and were well tolerated.</p><p><b>Basilar impression.</b> It is important to screen for this finding so that timely surgical intervention can be planned. A positive "Lhermitte's sign" (tingling in fingers with neck flexion) should prompt neurosurgical referral. Surgery is typically undertaken before persistent/permanent neurologic features are present. If surgery is undertaken, it should be done in a center experienced in the procedures used.</p><p><b>Dental treatment.</b> The goals are the maintenance of both primary and permanent dentition, functional bite or occlusion, optimal gingival health, and overall appearance. Pediatric dentists are the most knowledgeable about dentinogenesis imperfecta (DI) in children. Some consensus exists that early dental restorative coverage of the primary molars and (if possible) aesthetic coverage of the upper anterior teeth is optimal. Plastic polymers are sometimes used to coat teeth. As anxiety can be an issue with children, pre-medication for anxiolysis (e.g., nitrous oxide analgesia or midazolam) can be used for treatment in a clinic setting.</p><p>If warranted, orthodontic treatment can be initiated, but care must be taken in the use of orthodontic appliances because of the brittleness of the teeth.</p><p>Dental restorations in adults may best be done by a general dentist knowledgeable about OI or a specialist in prosthetic dentistry.</p><p><b>Hearing loss.</b> Surgical repair of the middle-ear bones and creation of a prosthetic incus can improve unaided hearing.</p><p>Later hearing loss appears to have a significant sensorineural component that does not respond to middle ear surgery. Cochlear implantation has been used in a small number of individuals; outcome data are limited.</p><p><b>Mental health support</b> through psychiatry/psychology and appropriate social worker intervention can improve quality of life.</p><p><b>Management of lethal OI.</b> It is appropriate to offer parents the option of allowing the infant to expire without attempting heroic interventions such as assisted ventilation.</p><p><b>Other therapies.</b> Early trials of anabolic steroids, sodium fluoride, testosterone, vitamins C and D, flavinoids, and calcitonin showed minimal or no improvement in bone formation, or too small a sample size was utilized for meaningful conclusions [reviewed in <a class="bk_pop" href="#oi.REF.byers.1992.269">Byers &#x00026; Steiner 1992</a>].</p></div><div id="oi.Prevention_of_Secondary_Complications"><h3>Prevention of Secondary Complications</h3><p>Special attention should be paid to anesthesia concerns including proper positioning on the operating room table, for which egg crate foam is recommended to avoid fractures.</p></div><div id="oi.Surveillance"><h3>Surveillance</h3><div id="oi.T.recommended_surveillance_for_indivi" class="table"><h3><span class="label">Table 9. </span></h3><div class="caption"><p>Recommended Surveillance for Individuals with <i>COL1A1/2</i> Osteogenesis Imperfecta</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1295/table/oi.T.recommended_surveillance_for_indivi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__oi.T.recommended_surveillance_for_indivi_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_oi.T.recommended_surveillance_for_indivi_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_oi.T.recommended_surveillance_for_indivi_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_oi.T.recommended_surveillance_for_indivi_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency</th></tr></thead><tbody><tr><td headers="hd_h_oi.T.recommended_surveillance_for_indivi_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Musculoskeletal</b></td><td headers="hd_h_oi.T.recommended_surveillance_for_indivi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Orthopedic evaluation</td><td headers="hd_h_oi.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Every 3 mos until age 1 yr, every 6 mos from 1 to 3 yrs, then annually or w/any new fractures</td></tr><tr><td headers="hd_h_oi.T.recommended_surveillance_for_indivi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Physical &#x00026; rehabilitation medicine</td><td headers="hd_h_oi.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Annually or more frequently if necessary for more severe clinical forms</td></tr><tr><td headers="hd_h_oi.T.recommended_surveillance_for_indivi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Physical therapy</td><td headers="hd_h_oi.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In infancy for individuals w/motor delays &#x00026; as needed to improve mobility &#x00026; function</td></tr><tr><td headers="hd_h_oi.T.recommended_surveillance_for_indivi_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_oi.T.recommended_surveillance_for_indivi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CT &#x00026;/or MRI examination w/views across base of skull to evaluate for basilar impression</td><td headers="hd_h_oi.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">If concerning signs or symptoms are present&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_oi.T.recommended_surveillance_for_indivi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Cervical spine flexion &#x00026; extension radiographs</td><td headers="hd_h_oi.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In children able to cooperate w/examination or before participating in sporting activities in more mildly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals</td></tr><tr><td headers="hd_h_oi.T.recommended_surveillance_for_indivi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Dental</b></td><td headers="hd_h_oi.T.recommended_surveillance_for_indivi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dental examinations</td><td headers="hd_h_oi.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2x/yr for those w/DI or at risk for DI</td></tr><tr><td headers="hd_h_oi.T.recommended_surveillance_for_indivi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Audiologic</b></td><td headers="hd_h_oi.T.recommended_surveillance_for_indivi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hearing evaluation</td><td headers="hd_h_oi.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Every 3-5 yrs from age 5 yrs until HL is identified, then as indicated based on nature &#x00026; degree of HL &#x00026; associated interventions</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">DI = dentinogenesis imperfecta; HL = hearing loss</p></div></dd><dt>1. </dt><dd><div id="oi.TF.9.1"><p class="no_margin">There is no universal agreement on when screening for basilar impression should be performed.</p></div></dd></dl></div></div></div></div><div id="oi.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Contact sports should be avoided.</p></div><div id="oi.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to clarify the genetic status of apparently asymptomatic older and younger at-risk relatives of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in order to identify as early as possible those who would benefit from cervical spine examination and dental and hearing evaluations.</p><p>See <a href="#oi.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="oi.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Fertility is normal in OI. Pregnancy in women with OI, especially those with progressively deforming OI, can be complicated because of a small pelvis, which may necessitate delivery by cesarean section. For most women who have mild non-deforming OI, pregnancy is uncomplicated. Joint laxity may increase, as it does with unaffected women, and reduce mobility in small, moderately <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> women. Bleeding is not more common than usual and complications of vaginal tearing during delivery are not common. Women with OI who are very small require pre-term cesarean section because of respiratory compromise. It is uncertain whether postpartum pelvic relaxation is more common. The mode of delivery of infants with OI has been examined to determine if the frequency of complications is higher with vaginal or cesarean section delivery. No difference in the frequency of complications was found. A higher-than-expected frequency of non-vertex presentations has been noted [<a class="bk_pop" href="#oi.REF.cubert.2001.66">Cubert et al 2001</a>]. The role of pregnancy in later fractures, loss of bone mineralization, progression of hearing loss, or any other physical consideration has not been examined in detail.</p><p>Women with OI who have significant skeletal deformity and short stature should be followed during pregnancy at a high-risk prenatal care center.</p><p>Cesarean section and vaginal delivery of an infant with OI have about the same rate of complications for each type of OI. Delivery of an infant with OI by cesarean section is more frequent than in the general population because a non-vertex presentation cannot be corrected by external manipulation.</p></div><div id="oi.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>RANK ligand antibodies, which inhibit osteoclast maturation, have been studied as a therapeutic option in children and results have shown an increase in vertebral body BMD, normalization of vertebral shape, and a reduction in vertebral compression fractures while on therapy. Ongoing studies are determining long-term efficacy and tolerance [<a class="bk_pop" href="#oi.REF.hoyerkuhn.2014.145">Hoyer-Kuhn et al 2014</a>, <a class="bk_pop" href="#oi.REF.hoyerkuhn.2016.24">Hoyer-Kuhn et al 2016</a>, <a class="bk_pop" href="#oi.REF.boyce.2017.283">Boyce 2017</a>].</p><p><b>Human growth hormone</b> has been evaluated as an adjunctive therapy in conjunction with bisphosphonates in a randomized controlled study. In this study, growth hormone therapy was reported to correlate with improved linear growth and increased BMD [<a class="bk_pop" href="#oi.REF.antoniazzi.2010.479">Antoniazzi et al 2010</a>]. An additional study presented similar results in 26 children with moderate to severe OI when growth hormone was used in isolation [<a class="bk_pop" href="#oi.REF.marini.2003.237">Marini et al 2003</a>].</p><p>Teriparatide, a PTH analog, has been used to treat osteoporosis and is being explored as an adjunctive therapy in OI [<a class="bk_pop" href="#oi.REF.orwoll.2014.491">Orwoll et al 2014</a>]. The risk for osteosarcoma in those treated with teriparatide has limited its widespread use in children with more severe forms of OI. An ongoing registry monitoring the risk in adults treated with teriparatide has not documented an instance of osteosarcoma in the eight years since it was established but longer observation is needed to identify the actual risk of osteosarcoma [<a class="bk_pop" href="#oi.REF.gilsenan.2018.2335">Gilsenan et al 2018</a>].</p><p><b>Bone marrow transplantation (BMT)</b> to introduce normal mesenchymal stem cells that have the capacity to differentiate into normal osteoblasts as well as transplanted mesenchymal stromal cells, which produce factors that stimulate endogenous bone growth in individuals with OI, has been evaluated in a pilot clinical trial. Preliminary data suggested a positive impact on growth [<a class="bk_pop" href="#oi.REF.otsuru.2012.1933">Otsuru et al 2012</a>, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00187018?term=osteogenesis+imperfecta&#x00026;rank=7" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.clinicaltrials.gov</a>].</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="oi.Genetic_Counseling"><h2 id="_oi_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="oi.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Classic non-deforming osteogenesis imperfecta (OI), perinatally lethal OI, progressively deforming OI, and common variable OI caused by pathogenic variants in <i>COL1A1</i> or <i>COL1A2</i> are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="oi.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Many individuals diagnosed with the milder forms of OI (classic non-deforming and some probands with common variable OI) have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>The proportion of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals who represent <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence of the disorder in a family) varies by the severity of disease. Approximately 60% of probands with mild OI represent simplex cases. Virtually 100% of probands with progressively deforming or perinatally lethal OI represent simplex cases and have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> or a pathogenic variant inherited from a parent with somatic and/or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include clinical examination of the parents and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if the variant in the proband has been identified.</div></li><li class="half_rhythm"><div>If the causative variant found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> variant in the proband or a very low level of <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> that includes the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> in a parent. The overall rate of parental mosaicism is up to 16% in families with dominant <i>COL1A1</i> or <i>COL1A2</i> causative variants, although the rate of very low levels of parental mosaicism, which can be difficult to detect in leukocyte DNA using standard molecular genetic techniques, may be higher [<a class="bk_pop" href="#oi.REF.pyott.2011.125">Pyott et al 2011</a>, <a class="bk_pop" href="#oi.REF.frederiksen.2016.972">Frederiksen et al 2016</a>].</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of the proband depends on the clinical/genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and/or is known to have the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the proband, the risk to the sibs is 50%. Intrafamilial clinical variability is observed among individuals with the same pathogenic variant.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a known <i>COL1A1</i> or <i>COL1A2</i> pathogenic or <a class="def" href="/books/n/gene/glossary/def-item/likely-pathogenic/">likely pathogenic variant</a> that cannot be detected in the leukocyte DNA of either parent, the <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> to the sibs of a proband is about 5% because of the significant possibility of parental somatic and/or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#oi.REF.pyott.2011.125">Pyott et al 2011</a>].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with a dominantly inherited form of OI has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, his or her family members are at risk.</p></div><div id="oi.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#oi.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the causative variant identified in the proband or clinical evidence of the disorder, the pathogenic variant may be <i>de novo</i>. However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="oi.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Testing</h3><p><b>High-risk pregnancies</b></p><ul><li class="half_rhythm"><div><b>Molecular genetic testing.</b> Once the OI-causing variant has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-testing/">preimplantation genetic testing</a> are possible.</div></li><li class="half_rhythm"><div><b>Biochemical analysis</b> of collagen from fetal cells is no longer offered clinically in the United States.</div></li><li class="half_rhythm"><div><b>Prenatal ultrasound examination</b> performed in a center with experience in diagnosing OI, done at the appropriate gestational age, can be a valuable tool in the <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> of OI. Normally, ultrasound examination detects only the lethal and most severe forms of OI prior to 20 weeks' gestation; milder forms may be detected later in pregnancy when fractures or deformity occurs:</div><ul><li class="half_rhythm"><div><b>Perinatally lethal OI.</b> The bony abnormalities can first be seen by ultrasound examination by about 13 to 14 weeks' gestation. By 16 weeks, femoral length is typically two or more weeks delayed, calvarial mineralization is essentially absent, and ribs generally have identified fractures.</div></li><li class="half_rhythm"><div><b>Progressively deforming OI.</b> Limb length generally begins to fall below the growth curve at about 17 to 18 weeks' gestation; serial ultrasound examinations are required to confirm the trend.</div></li></ul></li></ul><p>Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.</p><p><b>Low-risk pregnancies.</b> Routine prenatal ultrasound examination may identify a fetus not known to be at risk for <i>COL1A1/2</i>-OI with findings suggestive of OI (perinatally lethal OI or progressively deforming OI) including reduced echogenicity of fetal bones, bowed, crumpled femurs, beaded ribs, evidence of fractures, and markedly diminished calvarial mineralization. As a part of the evaluation of such findings, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>COL1A1/2</i> may be considered; however, inability to identify a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> does not rule out the diagnosis of OI in the fetus.</p></div></div><div id="oi.Resources"><h2 id="_oi_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="https://ghr.nlm.nih.gov/condition/osteogenesis-imperfecta" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Osteogenesis imperfecta</a></div></li><li class="half_rhythm"><div><b>Osteogenesis Imperfecta Foundation</b></div><div>804 West Diamond Avenue</div><div>Suite 210</div><div>Gaithersburg MD 20878</div><div><b>Phone:</b> 800-981-2663 (toll-free); 301-947-0083</div><div><b>Fax:</b> 301-947-0456</div><div><b>Email:</b> bonelink@oif.org</div><div><a href="http://www.oif.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.oif.org</a></div></li><li class="half_rhythm"><div><b>Brittle Bone Society (BBS)</b></div><div>Grant-Paterson House</div><div>30 Guthrie Street</div><div>Dundee DD1 5BS</div><div>United Kingdom</div><div><b>Phone:</b> 08000 282459 (Toll-free Helpline); 01382 204446</div><div><b>Fax:</b> 01382 206771</div><div><b>Email:</b> contact@brittlebone.org</div><div><a href="http://www.brittlebone.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.brittlebone.org</a></div></li><li class="half_rhythm"><div><b>Brittle Bone Disorders Consortium Contact Registry for People with OI</b></div><div>Osteogenesis Imperfecta Foundation</div><div><b>Phone:</b> 301-947-0083</div><div><b>Fax:</b> 844-889-7579</div><div><b>Email:</b> Bonelink@oif.org</div><div><a href="http://www.oif.org/site/PageServer?pagename=RS_LCRC" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Contact Registry</a></div></li></ul></div><div id="oi.Molecular_Genetics"><h2 id="_oi_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="oi.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>COL1A1/2 Osteogenesis Imperfecta: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1295/table/oi.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__oi.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_oi.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_oi.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_oi.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_oi.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_oi.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_oi.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_oi.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/1277" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>COL1A1</i></a></td><td headers="hd_b_oi.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=1277" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">17q21<wbr style="display:inline-block"></wbr>​.33</a></td><td headers="hd_b_oi.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P02452" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Collagen alpha-1(I) chain</a></td><td headers="hd_b_oi.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://oi.gene.le.ac.uk/home.php?select_db=COL1A1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Osteogenesis Imperfecta Mutation Database - COL1A1</a></td><td headers="hd_b_oi.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=COL1A1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COL1A1</a></td><td headers="hd_b_oi.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=COL1A1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COL1A1</a></td></tr><tr><td headers="hd_b_oi.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/1278" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>COL1A2</i></a></td><td headers="hd_b_oi.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=1278" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">7q21<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_oi.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P08123" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Collagen alpha-2(I) chain</a></td><td headers="hd_b_oi.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://oi.gene.le.ac.uk/home.php?select_db=COL1A2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Osteogenesis Imperfecta Mutation Database COL1A2</a></td><td headers="hd_b_oi.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=COL1A2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COL1A2</a></td><td headers="hd_b_oi.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=COL1A2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COL1A2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="oi.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="oi.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for COL1A1/2 Osteogenesis Imperfecta (<a href="/omim/120150,120160,166200,166210,166220,259420" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1295/table/oi.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__oi.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/120150" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">120150</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COLLAGEN, TYPE I, ALPHA-1; COL1A1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/120160" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">120160</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COLLAGEN, TYPE I, ALPHA-2; COL1A2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/166200" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">166200</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OSTEOGENESIS IMPERFECTA, TYPE I; OI1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/166210" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">166210</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OSTEOGENESIS IMPERFECTA, TYPE II; OI2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/166220" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">166220</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OSTEOGENESIS IMPERFECTA, TYPE IV; OI4</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/259420" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">259420</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OSTEOGENESIS IMPERFECTA, TYPE III; OI3</td></tr></tbody></table></div></div><div id="oi.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p><b>Introduction.</b>
<i>COL1A1</i> and <i>COL1A2</i> encode the &#x003b1;1 and &#x003b1;2 chains of collagen type I, a fibril-forming collagen found in most connective tissues and abundant in bone, cornea, dermis, and tendon. Collagen type I is a heterotrimer consisting of two &#x003b1;1 chains and one &#x003b1;2 chain. It is initially synthesized as a pro &#x003b1; chain with a propeptide at each end (N-propeptide and C-propeptide). The propeptides are necessary for pro &#x003b1; chain association and triple helix formation, which starts at the carboxy-terminal propeptide and extends to the amino-terminal propeptide.</p><p>Collagen type I contains a triple helical segment of 1,014 amino acids in which glycine is in every third position and prolines preceding glycine residues are generally hydroxylated, as are some lysyl residues in the Y-position of the Gly-X-Y triplet. Glycine, the smallest amino acid, must be in the third position to allow proper chain folding to occur.</p><p>The pathogenic variants in most families are unique; only a few recurrent variants (mostly CpG dinucleotides) are seen in more than one family.</p><p><b>Mechanism of disease causation.</b> In general, the primary mechanism for disease can be viewed as either quantitative or qualitative impacts on collagen type 1 protein. Quantitative changes, which lead to loss of function, tend to have a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> when compared to qualitative changes, which impart a <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> effect.</p><p>Classic non-deforming OI (quantitative, <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a>):</p><ul><li class="half_rhythm"><div>Decreased production of structurally normal type I procollagen results in a reduction in the amount of bone that can be made, leading to brittle bones.</div></li><li class="half_rhythm"><div>The vast majority of disease-causing variants are premature termination codons (e.g., frameshift, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants) that result in the reduction of <i>COL1A1</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> by half.</div></li></ul><p>Perinatally lethal OI, progressively deforming OI, and common variable OI (qualitative, <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a>):</p><ul><li class="half_rhythm"><div>Substitutions for glycine within the triple helical <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of the pro &#x003b1; chain delay triple helix formation, resulting in additional post-translation modification that prevents secretion of the assembled trimers.</div></li><li class="half_rhythm"><div>Small <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> deletions or duplications of single amino acids or Gly-X-Y triplets and <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>-skipping events may disrupt trimer assembly.</div></li><li class="half_rhythm"><div>Diminished amount of type I procollagen is secreted.</div></li><li class="half_rhythm"><div>Some of the protein in the matrix has an abnormal structure.</div></li><li class="half_rhythm"><div>Clinical consequence is influenced by the position of the substituted glycine, the chain in which the substitution occurs, and the nature of the substituting amino acid.</div></li><li class="half_rhythm"><div>Pathogenic variants closer to the 5' end of the protein are likely to result in milder clinical phenotypes due to chain association occurring at the carboxyl-terminal end of the chain.</div></li></ul></div></div><div id="oi.References"><h2 id="_oi_References_">References</h2><div id="oi.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="oi.REF.ablin.1990.1035">Ablin DS, Greenspan A, Reinhart M, Grix A. Differentiation of child abuse from osteogenesis imperfecta. <span><span class="ref-journal">AJR Am J Roentgenol. </span>1990;<span class="ref-vol">154</span>:1035–46.</span> [<a href="/pubmed/2108539" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2108539</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.ablin.1997.111">Ablin DS, Sane SM. Non-accidental injury: confusion with temporary brittle bone disease and mild osteogenesis imperfecta. <span><span class="ref-journal">Pediatr Radiol. </span>1997;<span class="ref-vol">27</span>:111–3.</span> [<a href="/pubmed/9028840" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9028840</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.adami.2003.126">Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, Tato L. Intravenous neridronate in adults with osteogenesis imperfecta. <span><span class="ref-journal">J Bone Miner Res. </span>2003;<span class="ref-vol">18</span>:126–30.</span> [<a href="/pubmed/12510813" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12510813</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.antoniazzi.2010.479">Antoniazzi F, Monti E, Venturi G, Franceschi R, Doro F, Gatti D, Zamboni G, Tat&#x000f2; L. GH in combination with bisphosphonate treatment in osteogenesis imperfecta. <span><span class="ref-journal">Eur J Endocrinol. </span>2010;<span class="ref-vol">163</span>:479–87.</span> [<a href="/pubmed/20592128" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20592128</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.ashournia.2015.149">Ashournia H, Johansen FT, Folkestad L, Diederichsen AC, Brixen K. Heart disease in patients with osteogenesis imperfecta - a systematic review. <span><span class="ref-journal">Int J Cardiol. </span>2015;<span class="ref-vol">196</span>:149–57.</span> [<a href="/pubmed/26100571" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26100571</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.bains.2019.e10118">Bains JS, Carter EM, Citron KP, Boskey AL, Shapiro JR, Steiner RD, Smith PA, Bober MB, Hart T, Cuthbertson D, Krischer J, Byers PH, Pepin M, Durigova M, Glorieux FH, Rauch F, Sliepka JM, Sutton VR, Lee B, Nagamani SC, Raggio CL, et al.  A multicenter observational cohort study to evaluate the effects of bisphosphonate exposure on bone mineral density and other health outcomes in osteogenesis imperfecta. <span><span class="ref-journal">JBMR Plus. </span>2019;<span class="ref-vol">3</span>:e10118</span> [<a href="/pmc/articles/PMC6524673/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6524673</span></a>] [<a href="/pubmed/31131341" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31131341</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.balasubramanian.2019.191">Balasubramanian M, Verschueren A, Kleevens S, Luyckx I, Perik M, Schirwani S, Mortier G, Morisaki H, Rodrigus I, Van Laer L, Verstraeten A, Loeys B. Aortic aneurysm/dissection and osteogenesis imperfecta: four new families and review of the literature. <span><span class="ref-journal">Bone. </span>2019;<span class="ref-vol">121</span>:191–5.</span> [<a href="/pubmed/30684648" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30684648</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.basel.2009.375">Basel D, Steiner RD. Osteogenesis imperfecta: recent findings shed new light on this once well-understood condition. <span><span class="ref-journal">Genet Med. </span>2009;<span class="ref-vol">11</span>:375–85.</span> [<a href="/pubmed/19533842" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19533842</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.ben_amor.2011.540178">Ben Amor IM, Glorieux FH, Rauch F. Genotype-phenotype correlations in autosomal dominant osteogenesis imperfecta. <span><span class="ref-journal">J Osteoporos. </span>2011;<span class="ref-vol">2011</span>:540178</span> [<a href="/pmc/articles/PMC3170785/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3170785</span></a>] [<a href="/pubmed/21912751" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21912751</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.bishop.2010.32">Bishop N, Harrison R, Ahmed F, Shaw N, Eastell R, Campbell M, Knowles E, Hill C, Hall C, Chapman S, Sprigg A, Rigby A. A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. <span><span class="ref-journal">J Bone Miner Res. </span>2010;<span class="ref-vol">25</span>:32–40.</span> [<a href="/pubmed/19580461" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19580461</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.bonafe.2015.2869">Bonafe L, Cormier-Daire V, Hall C, Lachman R, Mortier G, Mundlos S, Nishimura G, Sangiorgi L, Savarirayan R, Sillence D, Spranger J, Superti-Furga A, Warman M, Unger S. Nosology and classification of genetic skeletal disorders: 2015 revision. <span><span class="ref-journal">Am J Med Genet A. </span>2015;<span class="ref-vol">167A</span>:2869–92.</span> [<a href="/pubmed/26394607" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26394607</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.boyce.2017.283">Boyce AM. Denosumab: an emerging therapy in pediatric bone disorders. <span><span class="ref-journal">Curr Osteoporos Rep. </span>2017;<span class="ref-vol">15</span>:283–92.</span> [<a href="/pmc/articles/PMC5554707/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5554707</span></a>] [<a href="/pubmed/28643220" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28643220</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.budsamongkol.2019.138">Budsamongkol T, Intarak N, Theerapanon T, Yodsanga S, Porntaveetus T, Shotelersuk V. A novel mutation in COL1A2 leads to osteogenesis imperfecta/Ehlers-Danlos overlap syndrome with brachydactyly. <span><span class="ref-journal">Genes Dis. </span>2019;<span class="ref-vol">6</span>:138–46.</span> [<a href="/pmc/articles/PMC6545454/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6545454</span></a>] [<a href="/pubmed/31193991" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31193991</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.byers.1992.269">Byers PH, Steiner RD. Osteogenesis imperfecta. <span><span class="ref-journal">Annu Rev Med. </span>1992;<span class="ref-vol">43</span>:269–82.</span> [<a href="/pubmed/1580589" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1580589</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.byers.1988.237">Byers PH, Tsipouras P, Bonadio JF, Starman BJ, Schwartz RC. Perinatal lethal osteogenesis imperfecta (OI type II): a biochemically heterogeneous disorder usually due to new mutations in the genes for type I collagen. <span><span class="ref-journal">Am J Hum Genet. </span>1988;<span class="ref-vol">42</span>:237–48.</span> [<a href="/pmc/articles/PMC1715253/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1715253</span></a>] [<a href="/pubmed/3341380" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3341380</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.carty.1988.350">Carty H. Brittle or battered. <span><span class="ref-journal">Arch Dis Child. </span>1988;<span class="ref-vol">63</span>:350–2.</span> [<a href="/pmc/articles/PMC1778820/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1778820</span></a>] [<a href="/pubmed/3284477" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3284477</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.cepollaro.1999.129">Cepollaro C, Gonnelli S, Pondrelli C, Montagnani A, Martini S, Bruni D, Gennari C. Osteogenesis imperfecta: bone turnover, bone density, and ultrasound parameters. <span><span class="ref-journal">Calcif Tissue Int. </span>1999;<span class="ref-vol">65</span>:129–32.</span> [<a href="/pubmed/10430645" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10430645</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.charnas.1993.2603">Charnas LR, Marini JC. Communicating hydrocephalus, basilar invagination, and other neurologic features in osteogenesis imperfecta. <span><span class="ref-journal">Neurology. </span>1993;<span class="ref-vol">43</span>:2603–8.</span> [<a href="/pubmed/8255464" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8255464</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.chien.2002.593">Chien YH, Chu SY, Hsu CC, Hwu WL. Pamidronate treatment of severe osteogenesis imperfecta in a newborn infant. <span><span class="ref-journal">J Inherit Metab Dis. </span>2002;<span class="ref-vol">25</span>:593–5.</span> [<a href="/pubmed/12638943" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12638943</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.cole.1995.284">Cole WG, Dalgleish R. Perinatal lethal osteogenesis imperfecta. <span><span class="ref-journal">J Med Genet. </span>1995;<span class="ref-vol">32</span>:284–9.</span> [<a href="/pmc/articles/PMC1050377/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1050377</span></a>] [<a href="/pubmed/7643358" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7643358</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.cole.1992.112">Cole WG, Patterson E, Bonadio J, Campbell PE, Fortune DW. The clinicopathological features of three babies with osteogenesis imperfecta resulting from the substitution of glycine by valine in the pro alpha 1 (I) chain of type I procollagen. <span><span class="ref-journal">J Med Genet. </span>1992;<span class="ref-vol">29</span>:112–8.</span> [<a href="/pmc/articles/PMC1015850/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1015850</span></a>] [<a href="/pubmed/1613761" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1613761</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.cremin.1982.35">Cremin B, Goodman H, Spranger J, Beighton P. Wormian bones in osteogenesis imperfecta and other disorders. <span><span class="ref-journal">Skeletal Radiol. </span>1982;<span class="ref-vol">8</span>:35–8.</span> [<a href="/pubmed/7079781" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7079781</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.cubert.2001.66">Cubert R, Cheng EY, Mack S, Pepin MG, Byers PH. Osteogenesis imperfecta: mode of delivery and neonatal outcome. <span><span class="ref-journal">Obstet Gynecol. </span>2001;<span class="ref-vol">97</span>:66–9.</span> [<a href="/pubmed/11152910" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11152910</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.deodhar.1994.463">Deodhar AA, Woolf AD. Bone density measurement in osteogenesis imperfecta may well be important. <span><span class="ref-journal">Postgrad Med J. </span>1994;<span class="ref-vol">70</span>:463–4.</span> [<a href="/pmc/articles/PMC2397719/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2397719</span></a>] [<a href="/pubmed/8029175" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8029175</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.dittrich.2007.2120">Dittrich R, Heidbreder A, Rohsbach D, Schmalhorst J, Nassenstein I, Maintz D, Ringelstein EB, Nabavi DG, Kuhlenb&#x000e4;umer G. Connective tissue and vascular phenotype in patients with cervical artery dissection. <span><span class="ref-journal">Neurology. </span>2007;<span class="ref-vol">68</span>:2120–4.</span> [<a href="/pubmed/17562832" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17562832</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.doi.2007.226">Doi K, Nishimura H, Ohta Y, Kubo T. Stapes surgery in Japanese patients with osteogenesis imperfecta. <span><span class="ref-journal">Adv Otorhinolaryngol. </span>2007;<span class="ref-vol">65</span>:226–30.</span> [<a href="/pubmed/17245052" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17245052</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.dwan.2014.cd005088">Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. <span><span class="ref-journal">Cochrane Database Syst Rev. </span>2014;<span class="ref-vol">7</span>:CD005088</span> [<a href="/pubmed/25054949" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25054949</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.emery.2012">Emery AEH, Rimoin DL. 2012 <em>Recommendations of the International Committee for Constitutional Disorders of the Skeleton</em>. Elsevier; 2012.</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.faqeih.2009.461">Faqeih E, Roughley P, Glorieux FH, Rauch F. Osteogenesis imperfecta type III with intracranial hemorrhage and brachydactyly associated with mutations in exon 49 of COL1A2. <span><span class="ref-journal">Am J Med Genet A. </span>2009;<span class="ref-vol">149A</span>:461–5.</span> [<a href="/pubmed/19208385" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19208385</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.frederiksen.2016.972">Frederiksen AL, Duno M, Johnsen IB, Nielsen MF, Kr&#x000f8;ig&#x000e5;rd AB. Asymptomatic parental mosaicism for osteogenesis imperfecta associated with a new splice site mutation in COL1A2. <span><span class="ref-journal">Clin Case Rep. </span>2016;<span class="ref-vol">4</span>:972–8.</span> [<a href="/pmc/articles/PMC5054473/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5054473</span></a>] [<a href="/pubmed/27761249" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27761249</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.gilsenan.2018.2335">Gilsenan A, Harding A, Kellier-Steele N, Harris D, Midkiff K, Andrews E. The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years. <span><span class="ref-journal">Osteoporos Int. </span>2018;<span class="ref-vol">29</span>:2335–43.</span> [<a href="/pmc/articles/PMC6154045/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6154045</span></a>] [<a href="/pubmed/29978254" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29978254</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.hayes.1999.357">Hayes M, Parker G, Ell J, Sillence D. Basilar impression complicating osteogenesis imperfecta type IV: the clinical and neuroradiological findings in four cases. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>1999;<span class="ref-vol">66</span>:357–64.</span> [<a href="/pmc/articles/PMC1736265/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1736265</span></a>] [<a href="/pubmed/10084535" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10084535</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.horton.1980.19">Horton WA, Dockery N, Sillence D, Rimoin DL. An embedding method for histochemical studies of undecalcified skeletal growth plate. <span><span class="ref-journal">Stain Technol. </span>1980;<span class="ref-vol">55</span>:19–29.</span> [<a href="/pubmed/6158142" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6158142</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.hoyerkuhn.2016.24">Hoyer-Kuhn H, Franklin J, Allo G, Kron M, Netzer C, Eysel P, Hero B, Schoenau E, Semler O. Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial. <span><span class="ref-journal">J Musculoskelet Neuronal Interact. </span>2016;<span class="ref-vol">16</span>:24–32.</span> [<a href="/pmc/articles/PMC5089451/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5089451</span></a>] [<a href="/pubmed/26944820" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26944820</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.hoyerkuhn.2014.145">Hoyer-Kuhn H, Netzer C, Koerber F, Schoenau E, Semler O. Two years' experience with denosumab for children with osteogenesis imperfecta type VI. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2014;<span class="ref-vol">9</span>:145.</span> [<a href="/pmc/articles/PMC4180531/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4180531</span></a>] [<a href="/pubmed/25257953" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25257953</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.kuurila.2004.187">Kuurila K, Pynnonen S, Grenman R. Stapes surgery in osteogenesis imperfecta in Finland. <span><span class="ref-journal">Ann Otol Rhinol Laryngol. </span>2004;<span class="ref-vol">113</span>:187–93.</span> [<a href="/pubmed/15053199" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15053199</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.lee.1995.1352">Lee JH, Gamble JG, Moore RE, Rinsky LA. Gastrointestinal problems in patients who have type-III osteogenesis imperfecta. <span><span class="ref-journal">J Bone Joint Surg Am. </span>1995;<span class="ref-vol">77</span>:1352–6.</span> [<a href="/pubmed/7673285" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7673285</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.lund.1999.1083">Lund AM, Molgaard C, Muller J, Skovby F. Bone mineral content and collagen defects in osteogenesis imperfecta. <span><span class="ref-journal">Acta Paediatr. </span>1999;<span class="ref-vol">88</span>:1083–8.</span> [<a href="/pubmed/10565454" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10565454</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.lv.2018.179">Lv F, Liu Y, Xu X, Song Y, Li L, Jiang Y, Wang O, Xia W, Xing X. Zoledronic acid versus alendronate in the treatment of children with osteogenesis imperfecta: a 2-year clinical study. <span><span class="ref-journal">Endocr Pract. </span>2018;<span class="ref-vol">24</span>:179–88.</span> [<a href="/pubmed/29466057" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29466057</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.maioli.2019.1090">Maioli M, Gnoli M, Boarini M, Tremosini M, Zambrano A, Pedrini E, Mordenti M, Corsini S, D'Eufemia P, Versacci P, Celli M, Sangiorgi L. Genotype-phenotype correlation study in 364 osteogenesis imperfecta Italian patients. <span><span class="ref-journal">Eur J Hum Genet. </span>2019;<span class="ref-vol">27</span>:1090–100.</span> [<a href="/pmc/articles/PMC6777444/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6777444</span></a>] [<a href="/pubmed/30886339" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30886339</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.malfait.2007.387">Malfait F, Symoens S, De Backer J, Hermanns-L&#x000ea; T, Sakalihasan N, Lapi&#x000e8;re CM, Coucke P, De Paepe A. Three arginine to cysteine substitutions in the pro-alpha (I)-collagen chain cause Ehlers-Danlos syndrome with a propensity to arterial rupture in early adulthood. <span><span class="ref-journal">Hum Mutat. </span>2007;<span class="ref-vol">28</span>:387–95.</span> [<a href="/pubmed/17211858" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17211858</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.marini.2003.237">Marini JC, Hopkins E, Glorieux FH, Chrousos GP, Reynolds JC, Gundberg CM, Reing CM. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen. <span><span class="ref-journal">J Bone Miner Res. </span>2003;<span class="ref-vol">18</span>:237–43.</span> [<a href="/pubmed/12568401" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12568401</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.marini.1997.746">Marini JC, Gerber NL. Osteogenesis imperfecta. Rehabilitation and prospects for gene therapy. <span><span class="ref-journal">JAMA. </span>1997;<span class="ref-vol">277</span>:746–50.</span> [<a href="/pubmed/9042848" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9042848</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.marlowe.2002.382">Marlowe A, Pepin MG, Byers PH. Testing for osteogenesis imperfecta in cases of suspected non- accidental injury. <span><span class="ref-journal">J Med Genet. </span>2002;<span class="ref-vol">39</span>:382–6.</span> [<a href="/pmc/articles/PMC1735162/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735162</span></a>] [<a href="/pubmed/12070242" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12070242</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.mayer.1996.552">Mayer SA, Rubin BS, Starman BJ, Byers PH. Spontaneous multivessel cervical artery dissection in a patient with a substitution of alanine for glycine (G13A) in the alpha 1 (I) chain of type I collagen. <span><span class="ref-journal">Neurology. </span>1996;<span class="ref-vol">47</span>:552–6.</span> [<a href="/pubmed/8757037" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8757037</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.moosa.2019.836">Moosa S, Yamamoto GL, Garbes L, Keupp K, Beleza-Meireles A, Moreno CA, Valadares ER, de Sousa SB, Maia S, Saraiva J, Honjo RS, Kim CA, Cabral de Menezes H, Lausch E, Lorini PV, Lamounier A Jr, Carniero TCB, Giunta C, Rohrbach M, Janner M, Semler O, Beleggia F, Li Y, Yigit G, Reintjes N, Altm&#x000fc;ller J, N&#x000fc;rnberg P, Cavalcanti DP, Zabel B, Warman ML, Bertola DR, Wollnik B, Netzer C. Autosomal-Recessive Mutations in MESD Cause Osteogenesis Imperfecta. <span><span class="ref-journal">Am J Hum Genet. </span>2019;<span class="ref-vol">105</span>:836–43.</span> [<a href="/pmc/articles/PMC6817720/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6817720</span></a>] [<a href="/pubmed/31564437" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31564437</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.orwoll.2014.491">Orwoll ES, Shapiro J, Veith S, Wang Y, Lapidus J, Vanek C, Reeder JL, Keaveny TM, Lee DC, Mullins MA, Nagamani SC, Lee B. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. <span><span class="ref-journal">J Clin Invest. </span>2014;<span class="ref-vol">124</span>:491–8.</span> [<a href="/pmc/articles/PMC3904621/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3904621</span></a>] [<a href="/pubmed/24463451" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24463451</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.otsuru.2012.1933">Otsuru S, Gordon PL, Shimono K, Jethva R, Marino R, Phillips CL, Hofmann TJ, Veronesi E, Dominici M, Iwamoto M, Horwitz EM. Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms. <span><span class="ref-journal">Blood. </span>2012;2012;<span class="ref-vol">120</span>:1933–41.</span> [<a href="/pmc/articles/PMC3433095/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3433095</span></a>] [<a href="/pubmed/22829629" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22829629</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.paterson.1984.1694">Paterson CR, McAllion S, Stellman JL. Osteogenesis imperfecta after the menopause. <span><span class="ref-journal">N Engl J Med. </span>1984;<span class="ref-vol">310</span>:1694–6.</span> [<a href="/pubmed/6727948" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6727948</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.paterson.1994.104">Paterson CR, Mole PA. Bone density in osteogenesis imperfecta may well be normal. <span><span class="ref-journal">Postgrad Med J. </span>1994;<span class="ref-vol">70</span>:104–7.</span> [<a href="/pmc/articles/PMC2397654/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2397654</span></a>] [<a href="/pubmed/8170878" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8170878</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.plotkin.2004.16">Plotkin H. Syndromes with congenital brittle bones. <span><span class="ref-journal">BMC Pediatr. </span>2004;<span class="ref-vol">4</span>:16.</span> [<a href="/pmc/articles/PMC516444/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC516444</span></a>] [<a href="/pubmed/15339338" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15339338</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.plotkin.2000.1846">Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2000;<span class="ref-vol">85</span>:1846–50.</span> [<a href="/pubmed/10843163" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10843163</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.pyott.2011.125">Pyott SM, Pepin MG, Schwarze U, Yang K, Smith G, Byers PH. Recurrence of perinatal lethal osteogenesis imperfecta in sibships: parsing the risk between parental mosaicism for dominant mutations and autosomal recessive inheritance. <span><span class="ref-journal">Genet Med. </span>2011;<span class="ref-vol">13</span>:125–30.</span> [<a href="/pubmed/21239989" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21239989</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.robinson.2019.11">Robinson ME, Rauch F. Mendelian bone fragility disorders. <span><span class="ref-journal">Bone. </span>2019;<span class="ref-vol">126</span>:11–17.</span> [<a href="/pubmed/31039433" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31039433</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.sillence.1994.427">Sillence DO. Craniocervical abnormalities in osteogenesis imperfecta: genetic and molecular correlation. <span><span class="ref-journal">Pediatr Radiol. </span>1994;<span class="ref-vol">24</span>:427–30.</span> [<a href="/pubmed/7700720" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7700720</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.sillence.1979.101">Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. <span><span class="ref-journal">J Med Genet. </span>1979;<span class="ref-vol">16</span>:101–16.</span> [<a href="/pmc/articles/PMC1012733/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1012733</span></a>] [<a href="/pubmed/458828" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 458828</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.steiner.1996.542">Steiner RD, Pepin M, Byers PH. Studies of collagen synthesis and structure in the differentiation of child abuse from osteogenesis imperfecta. <span><span class="ref-journal">J Pediatr. </span>1996;<span class="ref-vol">128</span>:542–7.</span> [<a href="/pubmed/8618190" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8618190</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.stenson.2017.665">Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, Hussain M, Phillips AD, Cooper DN. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. <span><span class="ref-journal">Hum Genet. </span>2017;<span class="ref-vol">136</span>:665–77.</span> [<a href="/pmc/articles/PMC5429360/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5429360</span></a>] [<a href="/pubmed/28349240" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28349240</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.van_der_rijt.2003.717">van der Rijt AJ, Cremers CW. Stapes surgery in osteogenesis imperfecta: results of a new series. <span><span class="ref-journal">Otol Neurotol. </span>2003;<span class="ref-vol">24</span>:717–22.</span> [<a href="/pubmed/14501445" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14501445</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.van_dijk.2012.11">van Dijk FS, Byers PH, Dalgleish R, Malfait F, Maugeri A, Rohrbach M, Symoens S, Sistermans EA, Pals G. EMQN best practice guidelines for the laboratory diagnosis of osteogenesis imperfecta. <span><span class="ref-journal">Eur J Hum Genet. </span>2012;<span class="ref-vol">20</span>:11–9.</span> [<a href="/pmc/articles/PMC3234509/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3234509</span></a>] [<a href="/pubmed/21829228" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21829228</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.van_dijk.2010.736">van Dijk FS, Huizer M, Kariminejad A, Marcelis CL, Plomp AS, Terhal PA, Meijers-Heijboer H, Weiss MM, van Rijn RR, Cobben JM, Pals G. Complete COL1A1 allele deletions in osteogenesis imperfecta. <span><span class="ref-journal">Genet Med. </span>2010;<span class="ref-vol">12</span>:736–41.</span> [<a href="/pubmed/21113976" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21113976</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.ward.2011.355">Ward LM, Rauch F, Whyte MP, D'Astous J, Gates PE, Grogan D, Lester EL, McCall RE, Pressly TA, Sanders JO, Smith PA, Steiner RD, Sullivan E, Tyerman G, Smith-Wright DL, Verbruggen N, Heyden N, Lombardi A, Glorieux FH. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2011;<span class="ref-vol">96</span>:355–64.</span> [<a href="/pubmed/21106710" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21106710</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oi.REF.wenstrup.1990.975">Wenstrup RJ, Willing MC, Starman BJ, Byers PH. Distinct biochemical phenotypes predict clinical severity in nonlethal variants of osteogenesis imperfecta. <span><span class="ref-journal">Am J Hum Genet. </span>1990;<span class="ref-vol">46</span>:975–82.</span> [<a href="/pmc/articles/PMC1683590/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1683590</span></a>] [<a href="/pubmed/2339695" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2339695</span></a>]</div></li></ul></div></div><div id="oi.Chapter_Notes"><h2 id="_oi_Chapter_Notes_">Chapter Notes</h2><div id="oi.Author_Notes"><h3>Author Notes</h3><p>Dr Steiner is a pediatrician, clinical geneticist, and clinical biochemical geneticist. He specializes in inherited metabolic diseases and osteogenesis imperfecta. Dr Steiner runs an OI clinic at Shriners Hospital in Portland for evaluation of children with OI.</p><p><a href="https://www.rarediseasesnetwork.org/cms/bbd" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Brittle Bone Disorders Consortium</a></p></div><div id="oi.Author_History"><h3>Author History</h3><p>Jessica Adsit, MS, CGC; Legacy Center for Maternal Fetal Medicine (2013-2019)<br />Donald Basel, MD (2013-present)<br />Peter H Byers, MD; University of Washington Health Sciences Center (2003-2013)<br />Melanie G Pepin, MS, CGC; University of Washington Health Sciences Center (2003-2013)<br />Robert D Steiner, MD (2003-present)</p></div><div id="oi.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>12 December 2019 (aa) Revision: <i>MESD</i> added (<a class="figpopup" href="/books/NBK1295/table/oi.T.other_types_of_osteogenesis_imperfe/?report=objectonly" target="object" rid-figpopup="figoiTothertypesofosteogenesisimperfe" rid-ob="figoboiTothertypesofosteogenesisimperfe">Table 5</a>)</div></li><li class="half_rhythm"><div>19 September 2019 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>14 February 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>28 January 2005 (me) Review posted live</div></li><li class="half_rhythm"><div>14 June 2003 (rs) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1295</span><span class="label">PMID: <a href="/pubmed/20301472" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301472</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/clpb-def/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/col4a1-dis/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1295&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1295/?report=reader">PubReader</a></li><li><a href="/books/NBK1295/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1295" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1295" style="display:none" title="Cite this Page"><div class="bk_tt">Steiner RD, Basel D. COL1A1/2 Osteogenesis Imperfecta. 2005 Jan 28 [Updated 2019 Dec 12]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1295/pdf/Bookshelf_NBK1295.pdf">PDF version of this page</a> (685K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#oi.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#oi.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#oi.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#oi.Genetically_Related_Allelic_Disorders" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#oi.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#oi.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#oi.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#oi.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#oi.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#oi.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#oi.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1278[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">COL1A2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1277[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">COL1A1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1485560" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1485560" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1485560" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1485560" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25905334" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Osteogenesis Imperfecta</a><span class="source">[Endotext. 2000]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Osteogenesis Imperfecta<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Marini J, Smith SM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Endotext. 2000</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24830047" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">TRPV4</i>-Associated Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">TRPV4</i>-Associated Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Schindler A, Sumner C, Hoover-Fong JE. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301294" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Brashear A, Sweadner KJ, Cook JF, Swoboda KJ, Ozelius L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301329" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hypophosphatasia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hypophosphatasia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mornet E, Nunes ME. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31145570" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Apert Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Apert Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wenger TL, Hing AV, Evans KN. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301472" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301472" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04164775f66d18aa5b18ad">COL1A1/2 Osteogenesis Imperfecta - GeneReviews®</a><div class="ralinkpop offscreen_noflow">COL1A1/2 Osteogenesis Imperfecta - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:09:11-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE897BB5E040F0C100000000039F01AA&amp;ncbi_session=CE897BB5E0416461_0927SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1295%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1295&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1295/&amp;ncbi_pagename=COL1A1/2 Osteogenesis Imperfecta - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE897BB5E0416461_0927SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>